<?xml version="1.0" encoding="UTF-8"?>
<rr:ResultsReport xmlns:rr="http://integration.foundationmedicine.com/reporting" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd">
  <rr:CustomerInformation>
    <rr:ReferenceID>01-2024-00036721</rr:ReferenceID>
    <rr:CSN />
    <rr:TRF>ORD-1794439-01</rr:TRF>
    <rr:MRN>33045679</rr:MRN>
    <rr:PhysicianId>109266</rr:PhysicianId>
    <rr:NPI />
  </rr:CustomerInformation>
  <rr:ResultsPayload>
    <FinalReport xmlns:xsd="http://www.w3.org/2001/XMLSchema" StagingId="1439405" clinicalId="1440705" xsi:noNamespaceSchemaLocation="http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd">
      <Application>
        <ApplicationSettings>
          <ApplicationSetting>
            <Name>Statement</Name>
            <Value />
          </ApplicationSetting>
        </ApplicationSettings>
      </Application>
      <DemographicCorrectionDate />
      <ReportId>ORD-1794439-01</ReportId>
      <SampleName>US1709714.01</SampleName>
      <Version>0</Version>
      <Sample>
        <FM_Id>ORD-1794439-01</FM_Id>
        <SampleId>US1709714.01</SampleId>
        <BlockId>S112-69102E (PF24003)</BlockId>
        <TRFNumber>ORD-1794439-01</TRFNumber>
        <TestType>FoundationOne CDX</TestType>
        <SpecFormat>Slide Deck</SpecFormat>
        <ReceivedDate>2024-01-09</ReceivedDate>
        <processSites>
          <processSite address="150 Second St., 1st Floor, Cambridge, MA 02141" cliaNumber="22D2027531" locationID="1" locationName="Cambridge" processID="1" processName="Extracted DNA" />
          <processSite address="150 Second St., 1st Floor, Cambridge, MA 02141" cliaNumber="22D2027531" locationID="1" locationName="Cambridge" processID="1" processName="LC" />
        </processSites>
      </Sample>
      <PMI>
        <ReportId>ORD-1794439-01</ReportId>
        <MRN>33045679</MRN>
        <FullName>Hsieh, Yu-Ying</FullName>
        <FirstName>Yu-Ying</FirstName>
        <LastName>Hsieh</LastName>
        <SubmittedDiagnosis>Uterus endometrial adenocarcinoma papillary serous</SubmittedDiagnosis>
        <Gender>Female</Gender>
        <DOB>1963-09-21</DOB>
        <OrderingMD>Yeh, Yi-Chen</OrderingMD>
        <OrderingMDId>109266</OrderingMDId>
        <Pathologist>Not Provided</Pathologist>
        <CopiedPhysician1 />
        <MedFacilName>Taipei Veterans General Hospital</MedFacilName>
        <MedFacilID>205872</MedFacilID>
        <SpecSite>Uterus</SpecSite>
        <CollDate>2023-12-29</CollDate>
        <ReceivedDate>2024-01-09</ReceivedDate>
        <CountryOfOrigin>TW</CountryOfOrigin>
      </PMI>
      <PertinentNegatives />
      <Summaries alterationCount="27" clinicalTrialCount="35" resistiveCount="0" sensitizingCount="4" />
      <VariantProperties>
        <VariantProperty geneName="ASXL1" isVUS="true" variantName="R499C" />
        <VariantProperty geneName="ATM" isVUS="true" variantName="H231N" />
        <VariantProperty geneName="BCORL1" isVUS="true" variantName="L275V" />
        <VariantProperty geneName="CIC" isVUS="true" variantName="E1361Q,K1329N" />
        <VariantProperty geneName="DAXX" isVUS="true" variantName="I543M" />
        <VariantProperty geneName="DIS3" isVUS="true" variantName="A494V" />
        <VariantProperty geneName="KDR" isVUS="true" variantName="rearrangement" />
        <VariantProperty geneName="KMT2D (MLL2)" isVUS="true" variantName="R3342C" />
        <VariantProperty geneName="SPEN" isVUS="true" variantName="Q743E,S1152L" />
        <VariantProperty geneName="TBX3" isVUS="true" variantName="amplification" />
        <VariantProperty geneName="TNFAIP3" isVUS="true" variantName="S466R" />
      </VariantProperties>
      <priorTests />
      <Genes>
        <Gene>
          <Name>CCNE1</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>amplification</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="amplification" />
              </AlterationProperties>
              <Interpretation>CCNE1 encodes the protein cyclin E1, which plays a role in the regulated transition from the G1 to S phase by binding to and activating cyclin-dependent protein kinase 2 (CDK2). It also has a direct role in initiation of replication and the maintenance of genomic stability (Möröy and Geisen, 2004; 15147722). Amplification of chromosomal region 19q12-q13 has been demonstrated in many types of cancer, and CCNE1 is a well-studied gene within this amplicon (Leung et al., 2006; 16575401, Lin et al., 2000; 11156406). Increased copy number of CCNE1 is highly associated with overexpression of the cyclin E1 protein (Mayr et al., 2006; 16753589, Nakayama et al., 2010; 20336784). Cyclin E1 overexpression can lead to cell transformation as a result of an increase in cyclin E1 activity (Stamatakos et al., 2010; 21176227, Möröy and Geisen, 2004; 15147722). In the Uterine Corpus Endometrial Carcinoma TCGA dataset, putative amplification of CCNE1 has been found in 6% of cases (Cancer Genome Atlas Research Network., 2013; 23636398). CCNE1 amplification has been observed in 41% (11/27) of endometrial intraepithelial carcinomas (Kuhn et al., 2014; 24309323) and in a study of ovarian cancer, CCNE1 amplification was observed in 12 of 12 serous carcinoma samples and in 2 of 6 endometrioid carcinomas (Mayr et al., 2006; 16753589). Elevated cyclin E1 protein expression has been associated with poor prognosis in several cancer types, including endometrial and ovarian cancer (Keyomarsi et al., 2002; 12432043, Potemski et al., 2009; 19179977, Callagy et al., 2005; 15682439, Mayr et al., 2006; 16753589, Nakayama et al., 2010; 20336784). There are no approved therapies that directly target CCNE1 alterations. Because amplification or overexpression of CCNE1 leads to increased genomic instability though the ATR-CHK1-WEE1 pathway (Lin et al., 2017; 28331049, Chen et al., 2018; 30181387) and cyclin E1 promotes cell cycle progression in a complex with CDK2 (Möröy and Geisen, 2004; 15147722), clinical and preclinical studies have investigated inhibitors of ATR, CDK2, CHK1, HDAC, PKMYT1, and WEE1 as potential therapeutic approaches for tumors with CCNE1 activation. Clinical benefit has been reported for patients with recurrent high-grade serous ovarian carcinoma (HGSOC) with CCNE1 amplification or expression in response to treatment with the CHK1 inhibitor prexasertib (Lee et al., 2018; 29361470). Studies of the WEE1 inhibitor adavosertib observed PRs in patients with CCNE1-amplified HGSOC and ovarian cancer (Lheureux et al., 2021; 33485453, Oza et al., 2020; 32611648, Fu et al., 2023; 36469840). Similarly, in a Phase 2 study of patients with CCNE1-amplified solid tumors, adavosertib elicited an ORR of 27% with PRs reported for patients with ovarian cancer, urothelial carcinoma, or melanoma; median PFS was 4.1 months and median OS was 9.9 months (Fu et al., 2021; AACR abstract 974, Fu et al., 2023; 36469840). One study has reported a reduction in tumor CCNE1 levels in 4/6 lung and esophageal cancer cases following treatment with the HDAC inhibitor vorinostat (Ma et al., 2013; 23686769). Preclinical studies have demonstrated that cell lines and murine models with CCNE1 amplification or overexpression were sensitive to inhibitors of ATR (Toledo et al., 2011; 21552262, Buisson et al., 2015; 26365377), CDK2 (Yang et al., 2015; 26204491), PKMYT1 (Gallo et al., 2022; 35444283, Szychowski et al., 2022; 35880755), or WEE1 (Kok et al., 2020; 33028815, Chen et al., 2018; 30181387). However, other studies have shown that sensitivity of various cell lines to CDK2 inhibitors, including SNS-032, dinaciclib, and seliciclib, at clinically achievable doses, is largely independent of CCNE1 copy number or expression (Taylor-Harding et al., 2015; 25557169, Etemadmoghadam et al., 2013; 24004674, Scaltriti et al., 2011; 21321214, Nanos-Webb et al., 2012; 21695458).</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote>Strong preclinical and clinical data suggest that CCNE1 amplification may predict sensitivity to WEE1 inhibitors. Strong preclinical data suggest that CCNE1 amplification may predict sensitivity to PKMYT1 inhibitors.</ClinicalTrialNote>
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks>
                <ClinicalTrialLink nctId="NCT04768868">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05605509">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04814108">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT03968653">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05109975">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04855656">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05147272">
                  <Include>true</Include>
                </ClinicalTrialLink>
              </ClinicalTrialLinks>
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>FBXW7</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>R479Q</Name>
              <AlterationProperties>
                <AlterationProperty dnaFraction="16.48" isEquivocal="false" name="R479Q" />
              </AlterationProperties>
              <Interpretation>FBXW7 encodes the F-box protein subunit of the SCF ubiquitin ligase complex, which targets proteins for degradation (Welcker and Clurman, 2008; 18094723). FBXW7 inactivation is associated with chromosomal instability and with stabilization of proto-oncogenes, such as mTOR, MYC, cyclin E, NOTCH, and JUN; FBXW7 is therefore considered a tumor suppressor (Akhoondi et al., 2007; 17909001, Welcker and Clurman, 2008; 18094723). Alterations such as seen here may disrupt FBXW7 function or expression (Welcker et al., 2013; 24298052, Welcker et al., 2007; 17298674, Strohmaier et al., 2001; 11565034, Pashkova et al., 2010; 21070969, Akhoondi et al., 2007; 17909001, O'Neil et al., 2007; 17646409, Malyukova et al., 2013; 23228967, Thompson et al., 2007; 17646408). FBXW7 mutations have been reported in up to 14% of endometrial cancers (cBio-Zehir et al., 2017; 28481359, cBio-Cancer Genome Atlas Research Network, 2013; 23636398, cBio-Soumerai et al., 2018; 30068706). In primary endometrial carcinomas, FBXW7 mutations correlated with lymph node involvement (Garcia-Dios et al., 2013; 23219661). Reduced FBXW7 expression has been associated with poor prognosis in some cancers such as colorectal cancer, gastric cancer, esophageal SCC, cervical SCC, melanoma, non-small cell lung carcinoma, and osteosarcoma (Tu et al., 2012; 22548670, Iwatsuki et al., 2010; 19739118, Yokobori et al., 2012; 22576686, Yokobori et al., 2009; 19366810, Yokobori et al., 2014; 24165483, Rajagopalan et al., 2004; 14999283, Cheng et al., 2013; 23381582, Xu et al., 2016; 26954701, Li et al., 2015; 25622249). FBXW7 inactivating alterations may indicate sensitivity to mTOR inhibitors (Mao et al., 2008; 18787170, Yang et al., 2015; 25749036). Case series reported objective responses for 2 patients with FBXW7-mutated cervical squamous cell carcinoma treated with everolimus (Kulkarni et al., 2020; SGO Abstract 356).</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote>Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors.</ClinicalTrialNote>
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks>
                <ClinicalTrialLink nctId="NCT03239015">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04803318">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05125523">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT03297606">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT03203525">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05036226">
                  <Include>true</Include>
                </ClinicalTrialLink>
              </ClinicalTrialLinks>
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>KIT</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>amplification</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="true" name="amplification" />
              </AlterationProperties>
              <Interpretation>KIT (also called c-KIT) encodes a cell surface tyrosine kinase receptor that, upon ligand binding and dimerization, activates the PI3K-AKT and RAS-MAPK signaling pathways (Linnekin, 1999; 10582339). KIT aberrations, including point mutations, translocations, amplification, and overexpression, have been associated with various malignancies, and KIT is considered an oncoprotein (Fletcher, 2004; 15175998). KIT has been reported to be amplified in cancer (Gao et al., 2013; 23550210) and may be biologically relevant in this context (Zack et al., 2013; 24071852, Beroukhim et al., 2010; 20164920). KIT amplifications are common in various solid tumors, most often seen in mucosal melanomas (8-10%), adenoid cystic carcinomas (4.0%), small cell lung cancer (2.7%), and seminomas (2.1%)(cBio-Nguyen et al., 2022; 35120664). KIT expression has been reported in 58% (42/72) of endometrial adenocarcinomas in one study (Scobie et al., 2003; 12649669). KIT expression was correlated with worse overall survival for patients with endometrial cancer (Scobie et al., 2003; 12649669). Published data investigating the prognostic implications of KIT alterations in endometrial cancer are limited (PubMed, Jun 2023). On the basis of clinical evidence, primarily in gastrointestinal stromal tumor (GIST), melanoma, AML, and systemic mastocytosis, KIT activating alterations are associated with sensitivity to TKIs including imatinib, sunitinib, sorafenib, dasatinib, nilotinib, pazopanib, regorafenib, ponatinib, midostaurin, apatinib, avapritinib, and ripretinib (Heinrich et al., 2014; ASCO Abstract 10506, Heinrich et al., 2017; ASCO Abstract 11011, DeAngelo et al., 2017; ASH Abstract 2, Evans et al., 2017; 29093181, Abbaspour Babaei et al., 2016; 27536065, Ramaswamy et al., 2016; 27563456, Demetri et al., 2013; 23177515, Gotlib et al., 2016; 27355533, Jawhar et al., 2017; 28424161, Xu et al., 2014; 25031773, Gotlib et al., 2005; 15972446, George et al., 2018; ASCO Abstract 11511, Luo et al., 2017; 29066909, Janku et al., 2022; 35753087, Kim et al., 2022; ENA Abstract 237). The use of mTOR inhibitors as an alternative therapeutic strategy has demonstrated limited success in KIT-mutated, imatinib-resistant melanoma, with 1 PR and 3 SD observed for 4 patients treated with everolimus (Si et al., 2012; ASCO Abstract 8562, Si et al., 2012; 22162580). However, no responses were observed for 10 patients with mastocytosis following everolimus monotherapy, with 8/10 patients harboring the KIT D816V mutation (Parikh et al., 2010; 20038218). The role of KIT amplification as a biomarker for response to mTOR inhibitors has not been investigated (PubMed, Feb 2023). Clinical benefit has been observed for patients with KIT amplified or overexpressing tumors following treatment with imatinib (Wei et al., 2019; 30075827, Hodi et al., 2013; 23775962, Carvajal et al., 2011; 21642685, Guo et al., 2011; 21690468, Debiec-Rychter et al., 2005; 15685537, DeMatteo et al., 2009; 19303137, Faivre et al., 2005; 16135502, Hotte et al., 2005; 15659505, Alcedo et al., 2004; 15350030, Brandwein et al., 2011; 21403650, Reardon et al., 2009; 19904263), nilotinib (Lee et al., 2015; 26424760), sorafenib (Llovet et al., 2012; 22374331, Zhang et al., 2013; 23058498, Seino et al., 2014; 25450081, Li et al., 2009; 18846437), and sunitinib (Minor et al., 2012; 22261812, Mahipal et al., 2012; 23114504), suggesting that KIT amplification may be sensitive to these inhibitors. However, evidence demonstrating clinical benefit for regorafenib, dasatinib, pazopanib, or ponatinib in the context of KIT amplified or overexpressing tumors is limited.</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote>KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K-AKT-mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.</ClinicalTrialNote>
              <Therapies>
                <Therapy>
                  <Name />
                  <GenericName>Sunitinib</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Sunitinib is a small-molecule tyrosine kinase inhibitor that targets PDGFRs, VEGFRs, KIT, FLT3, CSF-1R, and RET. It is FDA approved for the treatment of advanced or metastatic pancreatic neuroendocrine tumors, gastrointestinal stromal tumors (GISTs) in patients who have progressed on or are intolerant to imatinib, and advanced renal cell carcinoma (RCC) as well as for the adjuvant treatment of patients at high risk of recurrent RCC after nephrectomy. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; On the basis of clinical and preclinical data in KIT-mutated (Minor et al., 2012; 22261812, Heinrich et al., 2008; 18955458, Buchbinder et al., 2015; 26264378, Reichardt et al., 2016; 26772734, Hirai et al., 2016; 27073655, Goemans et al., 2010; 20435347) or KIT-expressing tumors (Mahipal et al., 2012; 23114504, Minor et al., 2012; 22261812), KIT activating alterations may predict sensitivity to sunitinib. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; In a Phase 2 study, sunitinib elicited 18% (6/33) PR and 18% (6/33) SD rates in patients with endometrial carcinoma or carcinosarcoma, with median PFS and OS of 3 months and 19.4 months, respectively (Castonguay et al., 2014; 24882554). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Sorafenib</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Sorafenib is a kinase inhibitor that targets the RAF kinases, KIT, FLT3, RET, VEGFRs, and PDGFRs. It is FDA approved for the treatment of unresectable hepatocellular carcinoma, advanced renal cell carcinoma, and recurrent or metastatic differentiated thyroid carcinoma. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; On the basis of clinical and preclinical data in KIT-mutated (Quintás-Cardama et al., 2008; 18936790, Bisagni et al., 2009; 19461405, Handolias et al., 2010; 20372153, Disel et al., 2011; 20970876, Park et al., 2012; 22270258, Catania et al., 2014; 24855380, Guo et al., 2007; 17699867, Hu et al., 2008; 18483300) or KIT-expressing tumors (Llovet et al., 2012; 22374331, Zhang et al., 2013; 23058498, Seino et al., 2014; 25450081, Li et al., 2009; 18846437), KIT activating alterations may predict sensitivity to sorafenib. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; In a Phase 2 study of sorafenib for patients with advanced uterine carcinoma or carcinosarcoma, 5% (2/40) of patients with uterine carcinoma had a PR and 43% (17/40) had SD; no patients (0/16) with uterine carcinosarcoma had a PR and 25% (4/16) had SD (Nimeiri et al., 2010; 20117828). Sorafenib was found to demonstrate modest clinical activity for patients with recurrent ovarian cancer or primary peritoneal carcinomatosis in a Phase 2 clinical trial; however, considerable toxicity was observed (Matei et al., 2011; 21098323). Another Phase 2 study of sorafenib as third-line treatment for patients with epithelial ovarian cancer or primary peritoneal cancer showed no benefit, with none of the 11 patients exhibiting a PR, CR, or sustained SD (Bodnar et al., 2011; 21723597). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Nilotinib</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Nilotinib targets tyrosine kinases such as ABL (including BCR-ABL), PDGFRs, KIT, CSF1R, DDR1, and DDR2. It is FDA approved to treat newly diagnosed pediatric or adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, adults with Ph+ CML in chronic or accelerated phase with resistance or intolerance to prior therapy including imatinib, and pediatric patients with Ph+ CML in chronic phase with resistance or intolerance to prior tyrosine-kinase inhibitor therapy. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; On the basis of clinical and preclinical data in KIT-mutated (Lee et al., 2015; 26424760, Carvajal et al., 2015; 25695690, Hochhaus et al., 2015; 26002753, Blay et al., 2015; 25882987, Kaijimoto et al., 2015; 26722383), KIT-amplified (Lee et al., 2015; 26424760), or KIT-expressing tumors (Sako et al., 2014; 25221952), KIT activating alterations may confer sensitivity to nilotinib. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; Clinical data on the efficacy of nilotinib for the treatment of endometrial cancer are limited (PubMed, Dec 2023). Nilotinib has been primarily investigated as a therapeutic option for the treatment of chronic myeloid leukemia (CML) or gastrointestinal stromal tumors (GIST). In the context of CML, a Phase 3 clinical trial for patients who are Philadelphia chromosome (Ph) positive treated with imatinib or nilotinib (300 or 400 mg) reported PFS rates of 93% and 97-98% and OS rates of 93% and 94-97%, respectively, at 4 years (Hughes et al., 2014; 24335106). For Japanese patients with CML who are resistant to imatinib, a Phase 2 trial reported a 49% major medical response rate to treatment with nilotinib at 12 months (Takahashi et al., 2014; 24650752). A Phase 3 clinical trial of single-agent nilotinib in 240 patients with advanced GIST who failed prior treatment with imatinib or sunitinib reported no significant difference in PFS between nilotinib and the best supportive care but did report increased OS for patients treated with nilotinib (Reichardt et al., 2012; 22357255). A Phase 2 trial has shown that nilotinib was well tolerated and suggested it may be particularly useful for treating patients with GIST harboring mutations in KIT exon 17 (Cauchi et al., 2012; 22119758). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Imatinib</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Imatinib targets the BCR-ABL fusion protein, PDGFR, and KIT. It is FDA approved for the treatment of KIT-positive gastrointestinal stromal tumors (GIST), Ph+ chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), myelodysplastic syndrome/myeloproliferative syndrome (MDS/MPS), aggressive systemic mastocytosis without a D816V KIT mutation, hypereosinophilic syndrome and/or chronic eosinophilic leukemia, and dermatofibrosarcoma protuberans. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; On the basis of clinical and preclinical data in KIT-mutated (Carvajal et al., 2011; 21642685, Debiec-Rychter et al., 2006; 16624552, Heinrich et al., 2003; 14645423, Hodi et al., 2013; 23775962), KIT-amplified (Wei et al., 2019; 30075827, Guo et al., 2011; 21690468, Hodi et al., 2013; 23775962, Carvajal et al., 2011; 21642685), or KIT-expressing tumors (DeMatteo et al., 2009; 19303137, Faivre et al., 2005; 16135502, Alcedo et al., 2004; 15350030, Brandwein et al., 2011; 21403650, Hotte et al., 2005; 15659505, Reardon et al., 2009; 19904263, Kamenz et al., 2006; 16570351, Wang et al., 2005; 15650049), KIT activating alterations may confer sensitivity to imatinib. PDGFRA amplification may predict sensitivity to TKIs such as imatinib; a patient with Merkel cell carcinoma expressing PDGFRA achieved a CR to imatinib (Frenard et al., 2016; 27051816). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; A Phase 2 trial of imatinib for the treatment of uterine carcinosarcoma reported that the therapy was generally well tolerated but showed minimal activity in the 23 evaluable patients; positive PDGFR-beta or KIT expression was not correlated with patient characteristics or outcome (Huh et al., 2010; 20189232). A Phase 2 trial of imatinib plus docetaxel for patients with head and neck squamous cell carcinoma (HNSCC) or non-small cell lung cancer (NSCLC) was stopped due to toxicity and lack of efficacy (Tsao et al., 2011; 21892101). A Phase 2 study of pulse dose imatinib in combination with paclitaxel for elderly patients with NSCLC reported a response rate of 32% (11/34); however, PFS and OS was similar to that commonly seen for elderly patients with NSCLC treated with single-agent chemotherapy, and the combination was not recommended for further evaluation (Bauman et al., 2012; 23033932). Phase 2 clinical trials of imatinib for unselected patients with breast cancer did not demonstrate significant efficacy (Yardley et al., 2009; 19933079, Chew et al., 2008; 19073506). In addition, a Phase 2 study for 13 patients with metastatic breast cancer with no c-KIT expression and overexpression of PDGFR-beta reported that imatinib as a single agent displayed no clinical activity (Cristofanilli et al., 2008; 18515258). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
              </Therapies>
              <ReferenceLinks />
              <ClinicalTrialLinks>
                <ClinicalTrialLink nctId="NCT05007106">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04008797">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05112991">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05024214">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05098847">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04803318">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04977453">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05740215">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05554341">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT02693535">
                  <Include>true</Include>
                </ClinicalTrialLink>
              </ClinicalTrialLinks>
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>MDM2</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>amplification</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="amplification" />
              </AlterationProperties>
              <Interpretation>MDM2 encodes an E3 ubiquitin protein ligase, which mediates the ubiquitination and subsequent degradation of p53, Rb1, and other proteins (Sdek et al., 2005; 16337594, Brady et al., 2005; 15632057, Li et al., 2004; 15053880). MDM2 has been reported to be amplified in cancer (Beroukhim et al., 2010; 20164920) and may be biologically relevant in this context (Brown et al., 2009; 19935675, Cordon-Cardo et al., 1994; 8306343). MDM2 amplification is common in various solid tumors and is often seen in soft tissue sarcomas (19%), bladder (7.8%), bone (7.5%), glioma (6.3%), non-small cell lung (5.4%), hepatobiliary (4.5%), esophagogastric (4.4%), breast (4.1%), and germ cell tumor (3.8%) cancer (cBio-Zehir et al., 2017; 28481359). Expression of MDM2 protein has been identified in 42-70% (15/36-19/27) of endometrioid endometrial carcinomas and 36-67% (9/25-8/12) of papillary serous endometrial carcinomas (Edmondson et al., 2017; 28511869, Ambros et al., 1996; 8972476). One study observed that MDM2 protein expression was significantly associated with shorter overall survival (hazard ratio of 6) and an independent prognostic factor in high-risk endometrial cancer (Edmondson et al., 2017; 28511869). MDM2 antagonists disrupt the MDM2-p53 interaction, thereby stabilizing p53 (Cheok et al., 2011; 20975744). Preclinical studies have suggested that the amplification of MDM2, in the absence of concurrent TP53 mutations, may increase sensitivity to these agents (Ohnstad et al., 2013; 23165797, Gamble et al., 2012; 21725357). Preliminary Phase 1 studies of the MDM2-p53 antagonist alrizomadlin (APG-115) reported a PR in a patient with liposarcoma harboring an MDM2 amplification and wildtype for TP53 and SD in 21%–38% (6/28 and 5/13, respectively) of patients in genomically unselected solid tumors (Zhang et al., 2019; ASCO Abstract 3124, Rasco et al., 2019; ASCO Abstract 3126). A Phase 2 trial of alrizomadlin in combination with pembrolizumab reported a PR in 1 of 3 patients with malignant peripheral nerve sheath tumor that had failed standard therapy, as well as PRs in patients with multiple types of solid tumors that had failed immunotherapy, including 1 out of 14 patients with non-small cell lung cancer; 1 out of 5 patients with urothelial carcinoma; and 2 out of5, 1 out of 5, and 1 out of 11 patients with mucosal, uveal, and cutaneous melanoma, respectively (Tolcher et al., 2021; ASCO Abstract 2506). Phase 1b studies of the MDM2 inhibitor idasanutlin for refractory AML in combination with cytarabine or venetoclax reported anti-leukemic response rates of 33% (25/75) and 37% (11/30), respectively (Martinelli et al., 2016; EHA21 Abstract S504, Daver et al., 2018; ASH Abstract 767); clinical benefit (58% ORR, 7/12) with idasanutlin monotherapy has been reported for patients with polycythemia vera (Mascarenhas et al., 2019; ASH Abstract 134). The dual MDM2/MDM4 inhibitor ALRN-6924 led to an ORR of 27% (4/15) for patients with TP53 wildtype peripheral T-cell lymphoma in a Phase 2 study (Shustov et al., 2018; ASH Abstract 1623); responses have also been observed in TP53 wildtype AML, MDS, Merkel cell carcinoma, colorectal cancer, and liposarcoma (Sallman et al., 2018; ASH Abstract 4066, Meric-Bernstam et al., 2017; ASCO Abstract 2505).</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote>Inhibitors of the MDM2-p53 interaction are being tested in clinical trials. Overexpression or amplification of MDM2 may increase sensitivity to these agents, but more data are required.</ClinicalTrialNote>
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks>
                <ClinicalTrialLink nctId="NCT04785196">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT03611868">
                  <Include>true</Include>
                </ClinicalTrialLink>
              </ClinicalTrialLinks>
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>MYC</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>amplification</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="amplification" />
              </AlterationProperties>
              <Interpretation>MYC (c-MYC) encodes a transcription factor that regulates many genes related to cell cycle regulation and cell growth. It is an oncogene and may be activated in as many as 20% of cancers (Dang et al., 2006; 16904903). MYC dysregulation (amplification, overexpression, translocation) has been identified in a number of different cancer types (Nesbit et al., 1999; 10378696). MYC amplification has been significantly linked with increased mRNA and protein levels and results in the dysregulation of a large number of target genes (Blancato et al., 2004; 15083194, Dang et al., 2006; 16904903, Fromont et al., 2013; 23574779). In the Uterine Corpus Endometrioid Carcinoma TCGA dataset, putative high-level amplification of MYC has been found in 8% of cases (Cancer Genome Atlas Research Network., 2013; 23636398). In the scientific literature, MYC amplification has been detected in 15-27% of endometrial cancer cases (Konopka et al., 2004; 14663583, Williams et al., 1999; 10600396, Schraml et al., 1999; 10473073, Monk et al., 1994; 7977518). In one study, MYC amplification has been associated with higher tumor grade in uterine corpus cancers (Monk et al., 1994; 7977518). Limited clinical data indicates that MYC activation may predict sensitivity to the pan-MYC inhibitor OMO-103; a Phase 1 study for patients with solid tumors reported 7 SDs (n=18), including 8% tumor reduction in a patient with pancreas adenocarcinoma (Garralda et al., 2022; ENA Abstract 7). Preclinical data indicate MYC overexpression may predict sensitivity to investigational agents targeting CDK1 (Horiuchi et al., 2012; 22430491, Goga et al., 2007; 17589519), CDK2 (Molenaar et al., 2009; 19525400), Aurora kinase A (Dammert et al., 2019; 31375684, Mollaoglu et al., 2017; 28089889, Robert et al., 2017; 29088717, Wang et al., 2017; 28417568, Takahashi et al., 2015; 25632068, Li et al., 2018; 30226440, Mahadeva et al., 2014; 24893165, Park et al., 2019; 31429028) (Kong et al., 2017; DOI: 10.21037/tcr.2017.06.41), Aurora kinase B (Helfrich et al., 2016; 27496133, Hook et al., 2012; 22222631, Yang et al., 2010; 20643922, He et al., 2019; 30540594), glutaminase (Shroff et al., 2015; 25964345, Effenberger et al., 2017; 29156762, Shen et al., 2018; 30103944, Xiang et al., 2015; 25915584), or BET bromodomain-containing proteins (Delmore et al., 2011; 21889194, Bandopadhayay et al., 2013; 24297863, Loven et al., 2013; 23582323, Otto et al., 2019; 31734632), as well as agents targeting both HDAC and PI3K (Dong et al., 2013; 23866964, Pei et al., 2016; 26977882; Fu et al., 2019; 30224636). Exploratory biomarker analysis in a Phase 2 study reported a PFS benefit associated with a combination of the Aurora A kinase inhibitor alisertib and paclitaxel as second-line therapy for patients with MYC-overexpressed small cell lung cancer, but not for patients without MYC overexpression (Owonikoko et al., 2020; 31655296). A PR was reported for a patient with MYC-amplified invasive ductal breast carcinoma treated with an unspecified Aurora kinase inhibitor and taxol (Ganesan et al., 2014; 25253784). MYC amplification has also been suggested to predict response to chemotherapy in patients with breast cancer in some studies (Pereira et al., 2013; 23555992, Yasojima et al., 2011; 21741827). Preclinical evidence suggests that colon cancer cells with MYC amplification may be more sensitive to 5-fluorouracil and paclitaxel (Arango et al., 2001; 11406570, Bottone et al., 2003; 14516787).</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote>MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC-dependent transcriptional programs.</ClinicalTrialNote>
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks>
                <ClinicalTrialLink nctId="NCT05253053">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05110807">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04983810">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04686682">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05252390">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05327010">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05372640">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05053971">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04840589">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04587479">
                  <Include>true</Include>
                </ClinicalTrialLink>
              </ClinicalTrialLinks>
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>PDGFRA</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>amplification</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="amplification" />
              </AlterationProperties>
              <Interpretation>PDGFRA encodes platelet-derived growth factor receptor alpha (PDGFR-alpha), a tyrosine kinase receptor that, upon binding of cognate ligands (PDGFA or PDGFB), activates several signaling pathways, including PI3K and MAPK (Andrae et al., 2008; 18483217). PDGFR aberrations, including point mutations, translocations, amplification, and/or overexpression, have been associated with various malignancies (Fletcher, 2004; 15175998). Amplification of PDGFRA, frequently occurring with amplification of the genes KDR and KIT, has been associated with increased PDGFRA expression (Burford et al., 2013; 23990986, Flavahan et al., 2016; 26700815, Roszik et al., 2016; 26787600, Verhaak et al., 2010; 20129251) and poor prognosis (Burford et al., 2013; 23990986, Koschmann et al., 2016; 27582545, Phillips et al., 2013; 23438035, Puget et al., 2012; 22389665) in some subtypes of glioma. In the Uterine Corpus Endometrial Carcinoma Provisional TCGA dataset, putative high-level amplification of PDGFRA has been reported in fewer than 1% of cases (Cancer Genome Atlas Research Network., 2013; 23636398). High expression of PDGFR-alpha has been reported in both primary and recurrent endometrioid and uterine papillary serous endometrial carcinomas, and has been shown to be increased in recurrent as compared to primary cases (Slomovitz et al., 2004; 15385107). Increased PDGFR-alpha expression has been correlated with lower grade (grades 1 and 2) endometrial carcinomas (Slomovitz et al., 2004; 15385107). On the basis of limited evidence of clinical benefit for patients with increased PDGFR expression, PDGFRA amplification may be associated with sensitivity to imatinib (Frenard et al., 2016; 27051816, Geoerger et al., 2009; 19362466).</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote>PDGFRA amplification may predict sensitivity to imatinib and to anti-PDGFRA antibodies.</ClinicalTrialNote>
              <Therapies>
                <Therapy>
                  <Name />
                  <GenericName>Imatinib</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Imatinib targets the BCR-ABL fusion protein, PDGFR, and KIT. It is FDA approved for the treatment of KIT-positive gastrointestinal stromal tumors (GIST), Ph+ chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), myelodysplastic syndrome/myeloproliferative syndrome (MDS/MPS), aggressive systemic mastocytosis without a D816V KIT mutation, hypereosinophilic syndrome and/or chronic eosinophilic leukemia, and dermatofibrosarcoma protuberans. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; On the basis of clinical and preclinical data in KIT-mutated (Carvajal et al., 2011; 21642685, Debiec-Rychter et al., 2006; 16624552, Heinrich et al., 2003; 14645423, Hodi et al., 2013; 23775962), KIT-amplified (Wei et al., 2019; 30075827, Guo et al., 2011; 21690468, Hodi et al., 2013; 23775962, Carvajal et al., 2011; 21642685), or KIT-expressing tumors (DeMatteo et al., 2009; 19303137, Faivre et al., 2005; 16135502, Alcedo et al., 2004; 15350030, Brandwein et al., 2011; 21403650, Hotte et al., 2005; 15659505, Reardon et al., 2009; 19904263, Kamenz et al., 2006; 16570351, Wang et al., 2005; 15650049), KIT activating alterations may confer sensitivity to imatinib. PDGFRA amplification may predict sensitivity to TKIs such as imatinib; a patient with Merkel cell carcinoma expressing PDGFRA achieved a CR to imatinib (Frenard et al., 2016; 27051816). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; A Phase 2 trial of imatinib for the treatment of uterine carcinosarcoma reported that the therapy was generally well tolerated but showed minimal activity in the 23 evaluable patients; positive PDGFR-beta or KIT expression was not correlated with patient characteristics or outcome (Huh et al., 2010; 20189232). A Phase 2 trial of imatinib plus docetaxel for patients with head and neck squamous cell carcinoma (HNSCC) or non-small cell lung cancer (NSCLC) was stopped due to toxicity and lack of efficacy (Tsao et al., 2011; 21892101). A Phase 2 study of pulse dose imatinib in combination with paclitaxel for elderly patients with NSCLC reported a response rate of 32% (11/34); however, PFS and OS was similar to that commonly seen for elderly patients with NSCLC treated with single-agent chemotherapy, and the combination was not recommended for further evaluation (Bauman et al., 2012; 23033932). Phase 2 clinical trials of imatinib for unselected patients with breast cancer did not demonstrate significant efficacy (Yardley et al., 2009; 19933079, Chew et al., 2008; 19073506). In addition, a Phase 2 study for 13 patients with metastatic breast cancer with no c-KIT expression and overexpression of PDGFR-beta reported that imatinib as a single agent displayed no clinical activity (Cristofanilli et al., 2008; 18515258). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
              </Therapies>
              <ReferenceLinks />
              <ClinicalTrialLinks>
                <ClinicalTrialLink nctId="NCT04817956">
                  <Include>true</Include>
                </ClinicalTrialLink>
              </ClinicalTrialLinks>
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>BRAF</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>D594N</Name>
              <AlterationProperties>
                <AlterationProperty dnaFraction="3.05" isEquivocal="false" name="D594N" />
              </AlterationProperties>
              <Interpretation>BRAF encodes a member of the RAF family of protein kinases, which includes ARAF, BRAF, and CRAF. These kinases function downstream of RAS as part of the MAPK (RAF-MEK-ERK) signaling cascade that facilitates cell proliferation, survival and transformation (Holderfield et al., 2014; 24957944, Burotto et al., 2014; 24948110). BRAF mutations have been reported in up to 20% of all cancers, with the majority of mutations occurring at the V600 position (Davies et al., 2002; 12068308, Kandoth et al., 2013; 24132290). Alterations such as the class 3 mutation seen here have been shown to require concomitant upstream RAS activity in contrast with independently activating BRAF V600 or class 2 alterations (Wan et al., 2004; 15035987, Noeparast et al., 2016; 28947956, Smalley et al., 2009; 18794803, Smalley et al., 2009; 19351826, Ikenoue et al., 2004; 15150094, Sen et al., 2012; 22649091, Kamata et al., 2010; 20978199, Cardarella et al., 2013; 23833300, Niihori et al., 2006; 16474404, Moretti et al., 2009; 19735675, Rodriguez-Viciana et al., 2008; 18413255, Anastasaki et al., 2012; 22301711, Yao et al., 2017; 28783719, Sheikine et al., 2018; 32913992), and may activate the MEK-ERK signaling pathway via CRAF (Moretti et al., 2009; 19735675, Garnett et al., 2005; 16364920, Wan et al., 2004; 15035987, Smalley et al., 2009; 18794803, Noeparast et al., 2016; 28947956). BRAF mutations have been reported in 2.9% of endometrial carcinomas in the TCGA dataset (Cancer Genome Atlas Research Network., 2013; 23636398). In the literature, BRAF mutation has been generally been reported in 0-3% of endometrial carcinomas (Mizumoto et al., 2007; 17388789, Pappa et al., 2006; 16256179, Mutch et al., 2004; 15118616, Salvesen et al., 2005; 15723290), with two reports of 11-21% (Feng et al., 2005; 16144912, He et al., 2013; 23370429). Published data investigating the prognostic implications of BRAF alterations in endometrial carcinoma are limited (PubMed, Oct 2023). Clinical outcomes for patients with activating BRAF alterations treated with BRAF and MEK inhibitors are most extensive at the V600 codon; outcomes are more limited for BRAF class-3 kinase-impaired or inactivating mutations such as 1 or more of the alterations seen here. A retrospective study of immunotherapies in non-small cell lung cancer (NSCLC) reported a 78% (7/9) DCR for patients with BRAF class-3 mutations (Marin-Acevedo et al., 2021; ASCO Abstract e21016). MEK inhibitors alone or in combination with BRAF inhibitors may be efficacious in these alterations; a basket trial of the single-agent MEK inhibitor trametinib reported 1 PR, 8 SDs, and 9 PDs for these patients (Johnson et al., 2020; 31924734), and combination therapies reported individual responses in other basket trials (Nikanjam et al., 2021; 33722853, Nebhan et al., 2021; 33861486). A retrospective analysis in melanoma with BRAF mutations reported PD as the best response in BRAF class-3 alterations for 2 patients treated with MEK inhibitors and 3 patients treated with RAF inhibitors (Kim et al., 2017; 27911979). The single-agent BRAF inhibitor vemurafenib was not effective in a Phase 2 trial in NSCLC, which reported no responses for 6 patients with class-3 BRAF alterations (Mazieres et al., 2020; 31959346); a basket trial of vemurafenib also observed no responses for these patients (n=3) (Hainsworth et al., 2018; 29320312). Investigational BRAF inhibitors are also in development to target class-3 paradoxical activation (Spira et al., 2023; AACR Abstract CT032, Janku et al., 2021; AACR Abstract CT212); a Phase 1a/1b trial of the pan-RAF inhibitor exarafenib reported 1 PR for a patient with a BRAF class-3 mutation (Spira et al., 2023; AACR Abstract CT032). A basket trial of the ERK inhibitor ulixertinib reported no responses and 3 SDs for patients across tumors with class-3 mutations (Sullivan et al., 2018; 29247021).</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>FUBP1</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>deletion exons 2-11</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="deletion exons 2-11" />
              </AlterationProperties>
              <Interpretation>FUBP1 encodes far upstream element binding protein 1 (also called FBP-1), a DNA-binding protein reported to have roles in transcriptional activation and splicing regulation of target genes. It is believed to act as an oncogene in some tumor types, such as hepatocellular carcinoma and non-small-cell lung cancer (Rabenhorst et al., 2009; 19637194, Singer et al., 2009; 19258502), and as a tumor suppressor in others, particularly oligodendroglioma, for which mutations and/or loss of FUBP1 often co-occur with alterations in CIC or IDH1 (Sahm et al., 2012; 22588899, Bettegowda et al., 2011; 21817013, Baumgarten et al., 2014; 24117486, Chan et al., 2014; 24030748, Jiao et al., 2012; 22869205). FUBP1 alteration has been reported in 1.5% of samples analyzed in COSMIC, with the highest incidences reported in tumors of the endometrium (3.6%), central nervous system (3.2%), large intestine (3.0%), skin (2.8%), stomach (2.7%), and liver (2.6%) (COSMIC, Feb 2023)(Tate et al., 2019; 30371878). One study reported higher expression of FUBP1 in colorectal carcinoma tissues compared to adenoma and normal colon epithelial tissues (Jia et al., 2014; 25030436). A genetic signature defined by concomitant alterations in IDH1, CIC, and FUBP1 is associated with longer survival in patients with glioma (Jiao et al., 2012; 22869205). FUBP1 has been shown to activate the expression of MYC (Duncan et al., 1994; 8125259, Kim et al., 2003; 12819782, Weber et al., 2008; 19087307, Jang et al., 2009; 19219071), activate p27KIP1 (Zheng et al., 2011; 21855647), and regulate the splicing of MDM2 (Jacob et al., 2014; 24798327). Therapies targeting FUBP1 mutation directly or downstream effectors have not been tested preclinically or clinically in tumors that harbor FUBP1 mutations.</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>KDR</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>amplification</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="true" name="amplification" />
              </AlterationProperties>
              <Interpretation>KDR encodes vascular endothelial growth factor receptor 2 (VEGFR2), a member of the vascular endothelial growth factor receptor (VEGFR) family. It is a receptor tyrosine kinase that transmits signals from VEGFA and is involved in both tumor angiogenesis and vasculogenesis during development (Takahashi, 2011; 22130231). KDR amplification has been reported in many tumor types and may be oncogenic (Takahashi, 2011; 22130231). Amplification and mutation of KDR have been reported in fewer than 1% and 0.5-3.8% of endometrial cases, respectively (Cancer Genome Atlas Research Network., 2013; 23636398, cBio-Soumerai et al., 2018; 30068706). VEGFR-2 expression in endometrial carcinomas has been reported in 15-68% of cases in the scientific literature (Giatromanolaki et al., 2006; 16557278, Talvensaari-Mattila et al., 2005; 15867479, Dobrzycka et al., 2010; 20695190, Yokoyama et al., 2000; 10831352). In addition, increased levels of VEGF have been found in endometrial cancer tissue and correlated with increased expression and activity of VEGFR-2 (Koukourakis et al., 2011; 21208810, Giatromanolaki et al., 2006; 16557278, Talvensaari-Mattila et al., 2005; 15867479). VEGFR-2 expression has been associated with tumor grade, tumor stage, and poor prognosis in endometrial carcinoma (Piastowska-Ciesielska et al., 2013; 23273598, Giatromanolaki et al., 2006; 16557278, Sivridis, 2002; 11908694, Giatromanolaki et al., 2001; 11745191, Yokoyama et al., 2000; 10831352, Dobrzycka et al., 2010; 20695190). In one study, serum VEGF levels, but not tissue VEGFR-2 levels, correlated with tumor metastasis (Saarelainen et al., 2014; 24420153). For patients with recurrent fibrosarcoma harboring unspecified KDR mutations, a retrospective study reported an ORR of 25% (7/28) and DCR of 82% (23/28) following apatinib monotherapy treatment (Ma et al., 2020; 32158235). On the basis of clinical benefit for patients with clear cell renal cell carcinoma (ccRCC) (Beuselinck et al., 2018; 29095068, Song et al., 2015; 26228213, Dornbusch et al., 2013; 24086736, Terakawa et al., 2013; 21478036, You et al., 2015; 24710685) and a patient with breast angiosarcoma (Silva et al., 2015; 25639617), high VEGFR-2 expression has been associated with sensitivity to sunitinib. However, because data supporting concordance between VEGFR-2 expression and KDR genomic biomarkers are limited, it is unclear whether these therapeutic strategies would be beneficial in this case. Limited preclinical data suggest that KDR activating mutations may increase sensitivity to VEGFR2-targeted agents such as linifanib (Grillo et al., 2021; 33035615). On the basis of extensive clinical evidence across multiple tumor types, expression of plasma or tumor VEGFR-1 or VEGFR-2 has not been established as a reliable biomarker to predict response to the VEGFA-targeted agent bevacizumab (Baumgarten et al., 2016; 26627848, Sathornsumetee et al., 2008; 18182667, Olafson et al., 2019; 31582283, Nishikawa et al., 2013; ASCO Abstract 2023, Wick et al., 2013; WCN Abstract 1207, Duda et al., 2010; 20484123, Stremitzer et al., 2016; 27535973, Weickhardt et al., 2015; 26125443, Kopetz et al., 2009; 20008624, Miles et al., 2013; 23422754, Fountzilas et al., 2011; 21868552, Gianni et al., 2013; 23569311, Sánchez-Rovira et al., 2013; 23397155, Cameron et al., 2013; 23932548, Mok et al., 2014; 24807156, An et al., 2014; 24577128, Bais et al., 2017; 29059426, Cohen et al., 2009; 19201650, Van Cutsem et al., 2011; EMCC Abstract 803, Van Cutsem et al., 2012; 22565005, Lee et al., 2018; 29941486, Xu et al., 2009; 19826039, Heist et al., 2014; 25605928).</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>MED12</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>G44D</Name>
              <AlterationProperties>
                <AlterationProperty dnaFraction="31.15" isEquivocal="false" name="G44D" />
              </AlterationProperties>
              <Interpretation>MED12 encodes a subunit of the multi-protein mediator complex, an important transcriptional regulator (Clark et al., 2015; 26182352, Ding et al., 2008; 18691967). MED12/mediator has been implicated in regulating WNT/beta-catenin (Kim et al., 2006; 16565090, Kämpjärvi et al., 2016; 26383637), hedgehog/GLI (Zhou et al., 2006; 17000779), and TGF-beta (Huang et al., 2012; 23178117, Shaikhibrahim et al., 2014; 24938407) signaling, although the mechanisms by which MED12 mutations facilitate tumorigenesis are still poorly defined. Tumorigenic MED12 mutations have been shown to disrupt the composition and/or activity of the mediator complex (Turunen et al., 2014; 24746821, Kämpjärvi et al., 2014; 24980722, Kämpjärvi et al., 2016; 26383637). MED12 alterations, consisting predominantly of exon 2 mutations such as G44D, have been frequently reported in uterine leiomyomas (43-70%)(Mäkinen et al., 2011; 21868628, Mäkinen et al., 2014; 23913526, Ng et al., 2015; 26018969, Kämpjärvi et al., 2016; 27187686, Shahbazi et al., 2015; 26396919, Halder et al., 2015; 25325994, Markowski et al., 2014; 25272295, Piscuoglio et al., 2016; 26832993, Mishima et al., 2015; 26093648), smooth muscle tumors of uncertain malignant potential (STUMP; 11%)(Holzmann et al., 2015; 26637855, Perot et al., 2012; 22768200), breast phyllodes tumors (PTs; 8-74%)(Lien et al., 2016; 26860948, Cani et al., 2015; 25593300, Mishima et al., 2015; 26093648), and breast fibroadenomas (46-59%)(Lim et al., 2014; 25038752, Mishima et al., 2015; 26093648). Similar alterations have also been reported in uterine leiomyosarcomas (2-30%)(Corce and Chibon, 2015; 26037152, Ravegnini et al., 2013; 23222489, Perot et al., 2012; 22768200), and chronic lymphocytic leukemia (CLL; 5-8.8%)(Gueze et al., 2015; 26316624, Kämpjärvi et al., 2015; 25595892). In prostate cancer, MED12 mutations, localized to the central part of the protein rather than exon 2, have been reported in 1-5% of cases (Kämpjärvi et al., 2016; 26383637, Barbieri et al., 2012; 22610119, Yoon et al., 2016; 26924278). MED12 alterations are rare in other cancer types (Corce and Chibon, 2015; 26037152). In breast PTs, MED12 exon 2 mutation was diagnostic of breast PT compared to other spindle breast neoplasms (Lien et al., 2016; 26860948), correlated with decreased pathological grade in some studies (Yoon et al., 2016; 26856273, Piscuoglio et al., 2015; 25855048) but were independent of grade in others (Cani et al., 2015; 25593300, Yoshida et al., 2015; 25839987), and, according to one study, correlated with improved progression-free survival but increased risk of recurrence (Ng et al., 2015; 26018969). In one study, expression of an oncogenic MED12 exon 2 mutation in mice led to the development of leiomyomas and increased chromosome instability (Mittal et al., 2015; 26193636). There are no targeted therapies available to address genomic alterations in MED12. Uterine leiomyomas with tumorigenic MED12 alterations have been reported to overexpress IGF2 (Di Tommaso et al., 2014; 25015674). Also, in a preclinical study, BRD4 inhibition has been shown to release the mediator complex from select genomic sites and to inhibit mediator-mediated transcription (Bhagwat et al., 2016; 27068464), but whether BET inhibitors and/or IGF2 pathway inhibitors would be beneficial for patients with oncogenic MED12 alterations is unknown.</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>Microsatellite status</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>MS-Stable</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="MS-Stable" />
              </AlterationProperties>
              <Interpretation>Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA MMR in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite-stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS has been reported in 73-89% of endometrial cancers (Cancer Genome Research Atlas., 2013; 23636398, Black et al., 2006; 16549821, Mackay et al., 2010; 20304627, Kanopiene et al., 2014; 25458958, Hampel et al., 2006; 16885385, Steinbakk et al., 2011; 21547578, Bilbao et al., 2010; 20005452, Church et al., 2013; 23528559). TP53 mutations in microsatellite stable/mismatch repair-proficient (MMRp) POLE-wildtype endometrial carcinoma are indicative of a ProMisE/TCGA molecularly classified subtype, "p53abn" (NCCN Uterine Neoplasms Guidelines, v1.2023) (McCluggage et al., 2022; 34996131, Oaknin et al., 2022; 35690222, Cancer Genome Atlas Research Network et al., 2013; 23636398, Talhouk et al., 2015; 26172027, Concin et al., 2021; 33604759, Wu et al., 2022;36357827, Thiel et al., 2022; 35658479, Irshaid et al., 2023; 36857998, Trevaglino et al; 2022; 34536971), which is associated with high risk of recurrence (Leon-Castillo et al., 2022; 35078648), yet also with the highest degree of benefit from adjuvant chemoradiotherapy over radiotherapy relative to the other subtypes (Leon-Castillo et al., 2020; 32749941). Additionally, classification as this molecular subtype refines FIGO disease stage to IIC (Stage "IICm-p53abn") for patients with histologically determined Stage I/II early endometrial cancer that is locally confined to the uterine corpus or with myometrial invasion (Berek et al., 2023; 37337978). Data regarding the role of microsatellite instability on prognosis and survival in endometrial cancer are mixed (Zighelboim et al., 2007; 17513808, Kanopiene et al., 2014; 25458958, Bilbao-Sieyro et al., 2014; 25026289, Mackay et al., 2010; 20304627, Steinbakk et al., 2011; 21547578, Arabi et al., 2009; 19275958, Black et al., 2006; 16549821, Stelloo et al., 2016; 27006490, Mackay et al., 2010; 20304627, Nout et al., 2012; 22609107, Bilbao et al., 2010; 20005452), although these studies often evaluated endometrial cancers of all International Federation of Gynecology and Obstetrics (FIGO) stages together. On the basis of clinical evidence, MSS tumors are significantly less likely than MSI-H tumors to respond to anti-PD-1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI-H and experienced a significantly higher ORR compared with non-MSI-H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO-SITC Abstract P60).</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>SPOP</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>E46K</Name>
              <AlterationProperties>
                <AlterationProperty dnaFraction="19.67" isEquivocal="false" name="E46K" />
              </AlterationProperties>
              <Interpretation>SPOP encodes the substrate adapter of a ubiquitin ligase complex, which mediates the polyubiquitination and hence degradation of its substrate proteins such as the androgen, progesterone, and estrogen receptors, the bromodomain and extraterminal domain (BET) proteins BRD2, BRD3, and BRD4, and the DNA-damage response protein 53BP1 (An et al., 2014; 24508459, Cuneo et al., 2023; 36693379, Zhang et al., 2023; 36512624, Zhang et al., 2015; 25766326). SPOP is reported to function as a tumor suppressor in prostate cancer; however, it may play an oncogenic role in renal cell carcinoma (RCC) (Wang et al., 2020; 32355326, Song et al., 2020; 31901237). Most SPOP mutations in cancer cluster within the substrate-binding MATH domain (aa 31-161), and inactivating alterations in this domain inhibit the degradation of oncogenic protein substrates of SPOP (An et al., 2014; 24508459, Zhang et al., 2015; 25766326, Zhuang et al., 2009; 19818708, Blattner et al., 2014; 24563616). Although alterations such as observed here have not been characterized and their functional effect is unknown, they have been reported as hotspot mutations in prostate and endometrial cancers (Mani et al., 2014; 25058385, Ostertag et al., 2019; 31026449). Multiple mutations within the meprin and TRAF homology (MATH) MATH domain have been characterized and found to inactivate SPOP protein function (An et al., 2014; 24508459, Bernasocchi et al., 2022; 34974131). In the large MSK MetTropism genomic study, SPOP mutation was most frequently observed in prostate cancer (12.5%), endometrial cancer (3.3%), ovarian cancer (1.1%), small bowel cancer (1.1%), gastrointestinal neuroendocrine cancer (0.7%), and bladder and breast cancer (&lt;0.5%) (cBio-Nguyen et al., 2022; 35120664). Loss of SPOP protein expression is commonly observed and is reported most frequently in gastric (30%), colorectal (20%), and prostate (37%) tumors (Kim et al., 2013; 23216165). Published data investigating the prognostic implications of SPOP alterations in solid tumors other than prostate cancers are limited (PubMed, Mar 2023). SPOP inactivation leads to accumulation of its substrate proteins, including the androgen receptor (AR) (An et al., 2014; 24508459), and SPOP inactivating alterations in prostate cancer have been associated with increased clinical benefit from AR signaling inhibitors such as abiraterone, apalutamide, and enzalutamide (Boysen et al., 2018; 30068710, Swami et al., 2022; 36088616, McKay et al., 2021; 33849963, Stangl et al., 2021; ASCO Abstract 160, Abida et al., 2019; 31061129). It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>TP53</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>R248W</Name>
              <AlterationProperties>
                <AlterationProperty dnaFraction="13.06" isEquivocal="false" name="R248W" />
              </AlterationProperties>
              <Interpretation>Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Alterations such as seen here may disrupt TP53 function or expression (Joerger and Fersht, 2008; 18410249, Kato et al., 2003; 12826609, Kamada et al., 2011; 20978130, Zerdoumi et al., 2017; 28472496, Yamada et al., 2007; 17690113). TP53 mutations are frequent in endometrial carcinomas, having been reported in 17-54% of cases across multiple studies (Cancer Genome Atlas Research Network, 2013; 23636398, Dou et al., 2020; 32059776, Soumerai et al., 2020; 30068706). Among endometrial carcinoma subtypes, TP53 alteration is most common in endometrial serous carcinomas (88-94% of cases) (Cancer Genome Atlas Research Network, 2013; 23636398, Dou et al., 2020; 32059776, Soumerai et al., 2020; 30068706, Lin et al., 2022; 34998597). TP53 mutations in microsatellite stable/mismatch repair-proficient (MMRp) POLE-wildtype endometrial carcinoma are indicative of a ProMisE/TCGA molecularly classified subtype, "p53abn" (NCCN Uterine Neoplasms Guidelines, v1.2023) (McCluggage et al., 2022; 34996131, Oaknin et al., 2022; 35690222, Cancer Genome Atlas Research Network et al., 2013; 23636398, Talhouk et al., 2015; 26172027, Concin et al., 2021; 33604759, Wu et al., 2022;36357827, Thiel et al., 2022; 35658479, Irshaid et al., 2023; 36857998, Trevaglino et al; 2022; 34536971), which is associated with high risk of recurrence (Leon-Castillo et al., 2022; 35078648), yet also with the highest degree of benefit from adjuvant chemoradiotherapy over radiotherapy relative to the other subtypes (Leon-Castillo et al., 2020; 32749941). Additionally, classification as this molecular subtype refines FIGO disease stage to IIC (Stage "IICm-p53abn") for patients with histologically determined Stage I/II early endometrial cancer that is locally confined to the uterine corpus or with myometrial invasion (Berek et al., 2023; 37337978). In the context of endometrial carcinomas that are microsatellite stable (MSS)/mismatch repair-proficient (MMRp) and lack pathogenic POLE mutations, TP53 inactivating mutation or p53 nuclear expression is associated with poor prognosis (NCCN Uterine Neoplasms Guidelines, v1.2023)(Wild et al., 2012; 22678923, Lee et al., 2010; 20006376, Leon-Castillo et al., 2022; 35078648, Thiel et al., 2022; 35658479, McCluggage et al., 2022; 34996131, Oaknin et al., 2022; 35690222, Cancer Genome Atlas Research Network et al., 2013; 23636398, Talhouk et al., 2015; 26172027, Concin et al., 2021; 33604759, Wu et al., 2022;36357827, Thiel et al., 2022; 35658479, Irshaid et al., 2023; 36857998, Trevaglino et al; 2022; 34536971). Clinical and preclinical data suggest that solid tumors with TP53 mutations, such as R175H, Y220C, G245S, and R248W, may benefit from adoptive cell therapy targeting these specific TP53 mutations (Kim et al., 2022; 35749374, Zacharakis et al 2022; 35104158, Morelli et al., 2023; ASCO Abstract 2547). Clinical benefit has been reported for patients with breast cancer (2 PRs) (Kim et al., 2022; 35749374, Zacharakis et al 2022; 35104158), ovarian cancer (1 PR) (Kim et al., 2022; 35749374), and colorectal cancer (CRC; 1 SD) (Morelli et al., 2023; ASCO Abstract 2547) treated with tumor infiltrating lymphocyte-based or modified T-cell receptor-based adoptive cell therapy. There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633) or p53 gene therapy such as SGT53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628, Leung et al., 2021; ASCO Abstract 4139). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype (Leijen et al., 2016; 27601554). Phase 2 studies of adavosertib in combination with chemotherapy reported ORRs of 32% (30/94) and 41% (12/29) for patients with platinum-refractory TP53-mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513, Embaby et al., 2023; 37236033). For patients with platinum-sensitive TP53-mutated ovarian cancer, the combination of adavosertib with paclitaxel and carboplatin significantly increased PFS compared with paclitaxel and carboplatin alone (9.9 vs. 8.0 months) (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53-mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). The Phase 2 FOCUS4-C trial for patients with TP53- and RAS-mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring (Seligmann et al., 2021; 34538072). In a Phase 1b clinical trial of SGT-53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). Missense mutations leading to TP53 inactivation may be sensitive to therapies that reactivate mutated p53 such as eprenetapopt. In a Phase 1b trial for patients with p53-positive high-grade serous ovarian cancer, eprenetapopt combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR (Gourley et al., 2016; ASCO Abstract 5571). A Phase 1 trial of eprenetapopt with pembrolizumab for patients with solid tumors reported an ORR of 10% (3/29) (Park et al., 2022; 36084396). Adjuvant chemo(radio)therapy improved outcomes over radiotherapy alone for patients with endometrial carcinoma (EC) molecularly classified as TP53 abnormal (p53abn; as defined by TP53 mutation or either p53 IHC nuclear or cytoplasmic overexpression or null expression) in retrospective analyses (Jamieson et al., 2022; SGO Abstract 086, Leon-Castillo et al., 2020; 32749941), and this approach is recommended by the ESGO-ESTRO-ESP guidelines for this EC subtype (Concin et al., 2021; 33604759). For patients with p53abn high-risk EC treated in the PORTEC-3 trial, adjuvant platinum-based chemotherapy plus external beam radiotherapy (EBRT) significantly improved 5-year relapse-free survival (RFS; 59% vs. 36%, HR=0.52) and 5-year OS rates (65% vs. 42%, HR=0.55) versus EBRT alone (Leon-Castillo et al., 2020; 32749941). In another retrospective study, patients with concurrent TP53 mutation and p53 overexpression experienced significantly improved RFS (median 12.8 vs. 7.4 months, HR=0.41) and OS (median 30.0 vs. 14.4 months, HR=0.28) from bevacizumab plus chemotherapy over temsirolimus plus chemotherapy (Thiel et al., 2022; 35658479). One or more of the TP53 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with Li-Fraumeni syndrome (ClinVar, Sep 2023)(Landrum et al., 2018; 29165669). Follow-up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li-Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age-related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna-Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>Tumor Mutation Burden</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>07</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="07" />
              </AlterationProperties>
              <Interpretation>Tumor mutational burden (TMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitutions and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide-based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB level associated with lower rates of clinical benefit from treatment with PD-1- or PD-L1-targeting immune checkpoint inhibitors compared with patients with tumors harboring higher TMB levels, based on several studies in multiple solid tumor types (Goodman et al., 2017; 28835386, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). A large-scale genomic analysis found that endometrial adenocarcinomas harbored a median TMB of 4.5 Muts/Mb, and 15% of cases had an elevated TMB of greater than 20 Muts/Mb (FMI-Chalmers et al., 2017; 28420421). Another study evaluating TMB in endometrial adenocarcinoma reported that 24% of tumors had a mutational burden of greater than 10.4 Muts/Mb (Santin et al., 2016; ASCO Abstract 5591). Increased tumor mutational burden (TMB) in endometrial carcinoma has been correlated with POLE mutation and advanced high-grade endometrioid subtypes (Mehnert et al., 2016; 27159395, Cancer Genome Atlas Research Network, 2013; 23636398, Hussein et al., 2015; 25394778, Church et al., 2013; 23528559). Ultramutated endometrial tumors (elevated TMB with POLE mutations) have also been associated with improved PFS (Cancer Genome Atlas Research Network, 2013; 23636398). The same study associated lower mutational burden, independent of PD-L1 status, in endometrial carcinomas with poorer prognosis (Cancer Genome Atlas Research Network, 2013; 23636398). For patients with advanced microsatellite-stable endometrial carcinoma not treated with immunotherapy, OS did not significantly differ between patients with TMB-high (≥10 Muts/Mb) and TMB-low (11.4 vs. 13.5 months, adjusted HR=1.15) in 1 study (Shao et al., 2020; 33119110). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti-PD-1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple pan-tumor studies, increased tissue tumor mutational burden (TMB) was associated with sensitivity to immune checkpoint inhibitors (Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947, Ott et al., 2019; 30557521, Cristescu et al., 2022; 35101941, Friedman et al., 2022; 34876409, Sturgill et al., 2022; 35274716). In the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors, significant improvement in ORR was observed for patients with TMB ≥10 Muts/Mb (as measured by this assay) compared with those with TMB &lt;10 Muts/Mb in a large cohort that included multiple tumor types (Marabelle et al., 2020; 32919526); similar findings were observed in the KEYNOTE 028 and 012 trials (Cristescu et al., 2018; 30309915). At the same TMB cutpoint, retrospective analysis of patients with solid tumors treated with any checkpoint inhibitor identified that tissue TMB scores ≥ 10 Muts/Mb were associated with prolonged time to treatment failure compared with scores &lt;10 muts/Mb (HR=0.68) (Sturgill et al., 2022; 35274716). For patients with solid tumors treated with nivolumab plus ipilimumab in the CheckMate 848 trial, improved responses were observed in patients with a tissue TMB ≥ 10 Muts/Mb independent of blood TMB at any cutpoint in matched samples (Schenker at al., 2022; AACR Abstract 7845). However, support for higher TMB thresholds and efficacy was observed in the prospective Phase 2 MyPathway trial of atezolizumab for patients with pan-solid tumors, where improved ORR and DCR was seen in patients with TMB ≥ 16 Muts/Mb than those with TMB ≥ 10 and &lt;16 Muts/Mb (Friedman et al., 2022; 34876409). Similarly, analyses across several solid tumor types reported that patients with higher TMB (defined as ≥16-20 Muts/Mb) achieved greater clinical benefit from PD-1 or PD-L1-targeting monotherapy compared with patients with higher TMB treated with chemotherapy (Legrand et al., 2018; ASCO Abstract 12000) or those with lower TMB treated with PD-1 or PD-L1-targeting agents (Goodman et al., 2017; 28835386).</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
      </Genes>
      <Trials>
        <Trial>
          <Gene>CCNE1</Gene>
          <Alteration>amplification</Alteration>
          <Title>The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>WEE1</Target>
          <Locations>Taipei (Taiwan), Taoyuan (Taiwan), Taichung (Taiwan), Tainan (Taiwan), Shanghai (China), Wuhan (China), Beijing (China), Chengdu (China), Kansas, Texas</Locations>
          <NCTID>NCT04768868</NCTID>
          <Note>Strong preclinical and clinical data suggest that CCNE1 amplification may predict sensitivity to WEE1 inhibitors. Strong preclinical data suggest that CCNE1 amplification may predict sensitivity to PKMYT1 inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>CCNE1</Gene>
          <Alteration>amplification</Alteration>
          <Title>RP-6306 in Patients With Advanced Cancer</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>PKMYT1, ERBB2</Target>
          <Locations>Vancouver (Canada), Ottawa (Canada), Toronto (Canada), Kingston (Canada), London (Canada)</Locations>
          <NCTID>NCT05605509</NCTID>
          <Note>Strong preclinical and clinical data suggest that CCNE1 amplification may predict sensitivity to WEE1 inhibitors. Strong preclinical data suggest that CCNE1 amplification may predict sensitivity to PKMYT1 inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>CCNE1</Gene>
          <Alteration>amplification</Alteration>
          <Title>A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>WEE1</Target>
          <Locations>Oregon, Nevada, California, Arizona, Missouri, Ohio, Texas, New York</Locations>
          <NCTID>NCT04814108</NCTID>
          <Note>Strong preclinical and clinical data suggest that CCNE1 amplification may predict sensitivity to WEE1 inhibitors. Strong preclinical data suggest that CCNE1 amplification may predict sensitivity to PKMYT1 inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>CCNE1</Gene>
          <Alteration>amplification</Alteration>
          <Title>Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>WEE1</Target>
          <Locations>Groningen (Netherlands), Nijmegen (Netherlands), Leiden (Netherlands), Barcelona (Spain)</Locations>
          <NCTID>NCT03968653</NCTID>
          <Note>Strong preclinical and clinical data suggest that CCNE1 amplification may predict sensitivity to WEE1 inhibitors. Strong preclinical data suggest that CCNE1 amplification may predict sensitivity to PKMYT1 inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>CCNE1</Gene>
          <Alteration>amplification</Alteration>
          <Title>A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>WEE1</Target>
          <Locations>Bellinzona (Switzerland), Zürich (Switzerland), Michigan, Texas</Locations>
          <NCTID>NCT05109975</NCTID>
          <Note>Strong preclinical and clinical data suggest that CCNE1 amplification may predict sensitivity to WEE1 inhibitors. Strong preclinical data suggest that CCNE1 amplification may predict sensitivity to PKMYT1 inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>CCNE1</Gene>
          <Alteration>amplification</Alteration>
          <Title>Study of RP-6306 Alone or in Combination With RP-3500 in Patients With Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>PKMYT1, ATR</Target>
          <Locations>Copenhagen (Denmark), Utah, Toronto (Canada), Missouri, Massachusetts, Rhode Island, Connecticut, New York, Pennsylvania, Texas</Locations>
          <NCTID>NCT04855656</NCTID>
          <Note>Strong preclinical and clinical data suggest that CCNE1 amplification may predict sensitivity to WEE1 inhibitors. Strong preclinical data suggest that CCNE1 amplification may predict sensitivity to PKMYT1 inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>CCNE1</Gene>
          <Alteration>amplification</Alteration>
          <Title>Study of RP-6306 With Gemcitabine in Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>PKMYT1</Target>
          <Locations>London (United Kingdom), California, Arizona, Minnesota, Michigan, Toronto (Canada), New York, Pennsylvania, Florida</Locations>
          <NCTID>NCT05147272</NCTID>
          <Note>Strong preclinical and clinical data suggest that CCNE1 amplification may predict sensitivity to WEE1 inhibitors. Strong preclinical data suggest that CCNE1 amplification may predict sensitivity to PKMYT1 inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>FBXW7</Gene>
          <Alteration>R479Q</Alteration>
          <Title>Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>EGFR, ERBB4, ERBB2, PARP, mTOR, MET, ROS1, RET, VEGFRs, BRAF, CDK4, CDK6</Target>
          <Locations>Shanghai (China)</Locations>
          <NCTID>NCT03239015</NCTID>
          <Note>Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>FBXW7</Gene>
          <Alteration>R479Q</Alteration>
          <Title>Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK</Target>
          <Locations>Guangzhou (China)</Locations>
          <NCTID>NCT04803318</NCTID>
          <Note>Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>FBXW7</Gene>
          <Alteration>R479Q</Alteration>
          <Title>A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>mTOR</Target>
          <Locations>Tianjin (China)</Locations>
          <NCTID>NCT05125523</NCTID>
          <Note>Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>FBXW7</Gene>
          <Alteration>R479Q</Alteration>
          <Title>Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>ALK, ROS1, AXL, TRKA, MET, TRKC, EGFR, PARP, CDK4, CDK6, mTOR, MEK, BRAF, SMO</Target>
          <Locations>Vancouver (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)</Locations>
          <NCTID>NCT03297606</NCTID>
          <Note>Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>FBXW7</Gene>
          <Alteration>R479Q</Alteration>
          <Title>Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>VEGFA, mTOR</Target>
          <Locations>Texas</Locations>
          <NCTID>NCT03203525</NCTID>
          <Note>Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>FBXW7</Gene>
          <Alteration>R479Q</Alteration>
          <Title>COAST Therapy in Advanced Solid Tumors and Prostate Cancer</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>DDR2, ABL, SRC, KIT, mTOR</Target>
          <Locations>South Carolina</Locations>
          <NCTID>NCT05036226</NCTID>
          <Note>Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>KIT</Gene>
          <Alteration>amplification</Alteration>
          <Title>MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005)</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>PD-1, KIT, VEGFRs, FGFRs, PDGFRA, RET, TIGIT</Target>
          <Locations>Taoyuan (Taiwan), Tainan (Taiwan), Taipei (Taiwan), Seoul (Korea, Republic of), Osaka (Japan), Nagoya (Japan), Tokyo (Japan), Kashiwa (Japan), Alaska, Adana (Turkey)</Locations>
          <NCTID>NCT05007106</NCTID>
          <Note>KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K-AKT-mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>KIT</Gene>
          <Alteration>amplification</Alteration>
          <Title>A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>CBP, Beta-catenin, FGFRs, RET, PDGFRA, VEGFRs, KIT</Target>
          <Locations>Taipei (Taiwan), Taoyuan (Taiwan), Taichung (Taiwan), Tainan (Taiwan), Kurume (Japan), Matsuyama (Japan), Seongnamsi Bundang (Korea, Republic of), Songpa-gu (Korea, Republic of), Seoul (Korea, Republic of), Seodaemun (Korea, Republic of)</Locations>
          <NCTID>NCT04008797</NCTID>
          <Note>KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K-AKT-mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>KIT</Gene>
          <Alteration>amplification</Alteration>
          <Title>Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>PD-L1, FGFRs, RET, PDGFRA, VEGFRs, KIT</Target>
          <Locations>Fuzhou (China), Hangzhou (China), Ganzhou (China), Shanghai (China), Nanjing (China), Guangzhou (China), Changsha (China), Wuhan (China), Yueyang (China), Linyi (China)</Locations>
          <NCTID>NCT05112991</NCTID>
          <Note>KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K-AKT-mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>KIT</Gene>
          <Alteration>amplification</Alteration>
          <Title>Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>PD-L1, FGFRs, RET, PDGFRA, VEGFRs, KIT, FLT3, CSF1R</Target>
          <Locations>Hangzhou (China), Shanghai (China), Dongguan (China), Guangzhou (China), Zhuhai (China), Benbu (China), Zhengzhou (China), Jinan (China), Dalian (China), Tianjin (China)</Locations>
          <NCTID>NCT05024214</NCTID>
          <Note>KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K-AKT-mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>KIT</Gene>
          <Alteration>amplification</Alteration>
          <Title>Cryoablation Combined With Sintilimab Plus Lenvatinib In Previously Treated Unresectable Liver Metastasis From Solid Tumors</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>FGFRs, RET, PDGFRA, VEGFRs, KIT, PD-1</Target>
          <Locations>Shanghai (China)</Locations>
          <NCTID>NCT05098847</NCTID>
          <Note>KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K-AKT-mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>KIT</Gene>
          <Alteration>amplification</Alteration>
          <Title>Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK</Target>
          <Locations>Guangzhou (China)</Locations>
          <NCTID>NCT04803318</NCTID>
          <Note>KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K-AKT-mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>KIT</Gene>
          <Alteration>amplification</Alteration>
          <Title>GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>FGFRs, RET, PDGFRA, VEGFRs, KIT, PD-1, CTLA-4</Target>
          <Locations>Daejeon (Korea, Republic of), Suwon-si (Korea, Republic of), Seoul (Korea, Republic of), New York, North Carolina</Locations>
          <NCTID>NCT04977453</NCTID>
          <Note>KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K-AKT-mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>KIT</Gene>
          <Alteration>amplification</Alteration>
          <Title>Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>PD-1, FGFRs, RET, PDGFRA, VEGFRs, KIT</Target>
          <Locations>Chongqing (China)</Locations>
          <NCTID>NCT05740215</NCTID>
          <Note>KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K-AKT-mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>KIT</Gene>
          <Alteration>amplification</Alteration>
          <Title>Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>ABL, KIT</Target>
          <Locations>Washington, Oregon, Idaho, Montana</Locations>
          <NCTID>NCT05554341</NCTID>
          <Note>KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K-AKT-mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>KIT</Gene>
          <Alteration>amplification</Alteration>
          <Title>TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>CDK4, CDK6, FLT3, VEGFRs, CSF1R, KIT, RET, mTOR, ERBB2, MEK, BRAF, PARP, PD-1, CTLA-4, PD-L1, TRKB, ALK, TRKC, ROS1, TRKA, FGFRs</Target>
          <Locations>Washington, Oregon, California</Locations>
          <NCTID>NCT02693535</NCTID>
          <Note>KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K-AKT-mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>MDM2</Gene>
          <Alteration>amplification</Alteration>
          <Title>APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>PD-1, MDM2</Target>
          <Locations>Shanghai (China), Guangzhou (China)</Locations>
          <NCTID>NCT04785196</NCTID>
          <Note>Inhibitors of the MDM2-p53 interaction are being tested in clinical trials. Overexpression or amplification of MDM2 may increase sensitivity to these agents, but more data are required.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>MDM2</Gene>
          <Alteration>amplification</Alteration>
          <Title>A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>MDM2, PD-1</Target>
          <Locations>Brisbane (Australia), South Brisbane (Australia), Bedford Park (Australia), Heidelberg (Australia), California, Arizona, Missouri, Arkansas, Ohio, Pennsylvania</Locations>
          <NCTID>NCT03611868</NCTID>
          <Note>Inhibitors of the MDM2-p53 interaction are being tested in clinical trials. Overexpression or amplification of MDM2 may increase sensitivity to these agents, but more data are required.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>MYC</Gene>
          <Alteration>amplification</Alteration>
          <Title>Study to Evaluate the Efficacy and Safety of TT-00420 as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>FGFR2, FGFR1, FGFR3, PD-L1</Target>
          <Locations>Shanghai (China), Wuhu (China), Nanjing (China), Changsha (China), Zhengzhou (China), Jinan (China), Beijing (China), Changchun (China)</Locations>
          <NCTID>NCT05253053</NCTID>
          <Note>MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC-dependent transcriptional programs.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>MYC</Gene>
          <Alteration>amplification</Alteration>
          <Title>A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3617 Capsule in Patients With Advanced Malignant Tumors</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>BRD3, BRD4 , BRD2, BRDT</Target>
          <Locations>Hangzhou (China), Guangzhou (China)</Locations>
          <NCTID>NCT05110807</NCTID>
          <Note>MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC-dependent transcriptional programs.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>MYC</Gene>
          <Alteration>amplification</Alteration>
          <Title>A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>CDK2, CDK9</Target>
          <Locations>Seoul (Korea, Republic of), Barcelona (Spain), California, Texas</Locations>
          <NCTID>NCT04983810</NCTID>
          <Note>MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC-dependent transcriptional programs.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>MYC</Gene>
          <Alteration>amplification</Alteration>
          <Title>A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>BRD2, BRD3, BRD4, BRDT</Target>
          <Locations>Tianjin (China)</Locations>
          <NCTID>NCT04686682</NCTID>
          <Note>MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC-dependent transcriptional programs.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>MYC</Gene>
          <Alteration>amplification</Alteration>
          <Title>NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>BRD4, PARP, AR</Target>
          <Locations>Nedlands (Australia), Waratah (Australia), North Ryde (Australia), Melbourne (Australia), Malvern (Australia), Montana, California, Colorado</Locations>
          <NCTID>NCT05252390</NCTID>
          <Note>MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC-dependent transcriptional programs.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>MYC</Gene>
          <Alteration>amplification</Alteration>
          <Title>Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>PARP, BRD4, BRDT, BRD2, BRD3</Target>
          <Locations>California, Colorado, Illinois, Pennsylvania, Kentucky, Virginia, Texas</Locations>
          <NCTID>NCT05327010</NCTID>
          <Note>MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC-dependent transcriptional programs.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>MYC</Gene>
          <Alteration>amplification</Alteration>
          <Title>Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma and Other Solid Tumors</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>CDK4, CDK6, BRD3, BRD4, BRD2, BRDT</Target>
          <Locations>California, Pennsylvania, Massachusetts, Texas</Locations>
          <NCTID>NCT05372640</NCTID>
          <Note>MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC-dependent transcriptional programs.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>MYC</Gene>
          <Alteration>amplification</Alteration>
          <Title>Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>BRD3, BRD4, BRD2, BRDT, HDAC</Target>
          <Locations>Oklahoma, Connecticut, Florida</Locations>
          <NCTID>NCT05053971</NCTID>
          <Note>MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC-dependent transcriptional programs.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>MYC</Gene>
          <Alteration>amplification</Alteration>
          <Title>Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>PD-1, CTLA-4, BRD4, BRDT, BRD2, BRD3</Target>
          <Locations>Ohio, Pennsylvania, New York, Maryland</Locations>
          <NCTID>NCT04840589</NCTID>
          <Note>MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC-dependent transcriptional programs.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>MYC</Gene>
          <Alteration>amplification</Alteration>
          <Title>A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>BRD2, BRD3, BRD4, BRDT</Target>
          <Locations>Colorado, Tennessee, Florida</Locations>
          <NCTID>NCT04587479</NCTID>
          <Note>MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC-dependent transcriptional programs.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>PDGFRA</Gene>
          <Alteration>amplification</Alteration>
          <Title>Improving Public Cancer Care by Implementing Precision Medicine in Norway</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>PD-L1, VEGFA, ERBB2, ALK, RET, PARP, SMO, TRKB, TRKC, ROS1, TRKA, MEK, BRAF, PI3K-alpha, FGFR1, FGFR2, FGFR3, MET, KIT, ABL</Target>
          <Locations>Tromsø (Norway), Bodø (Norway), Hamar (Norway), Oslo (Norway), Fredrikstad (Norway), Drammen (Norway), Trondheim (Norway), Skien (Norway), Førde (Norway), Bergen (Norway)</Locations>
          <NCTID>NCT04817956</NCTID>
          <Note>PDGFRA amplification may predict sensitivity to imatinib and to anti-PDGFRA antibodies.</Note>
          <Include>true</Include>
        </Trial>
      </Trials>
      <References>
        <Reference number="0">
          <ReferenceId>18094723</ReferenceId>
          <FullCitation>Welcker M, et al. Nat. Rev. Cancer (2008) pmid: 18094723</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="1">
          <ReferenceId>17909001</ReferenceId>
          <FullCitation>Akhoondi S, et al. Cancer Res. (2007) pmid: 17909001</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="2">
          <ReferenceId>24298052</ReferenceId>
          <FullCitation>Welcker M, et al. Genes Dev. (2013) pmid: 24298052</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="3">
          <ReferenceId>17298674</ReferenceId>
          <FullCitation>Welcker M, et al. Cell Div (2007) pmid: 17298674</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="4">
          <ReferenceId>11565034</ReferenceId>
          <FullCitation>Strohmaier H, et al. Nature (2001) pmid: 11565034</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="5">
          <ReferenceId>21070969</ReferenceId>
          <FullCitation>Pashkova N, et al. Mol. Cell (2010) pmid: 21070969</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="6">
          <ReferenceId>17646409</ReferenceId>
          <FullCitation>O'Neil J, et al. J. Exp. Med. (2007) pmid: 17646409</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="7">
          <ReferenceId>23228967</ReferenceId>
          <FullCitation>Malyukova A, et al. Leukemia (2013) pmid: 23228967</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="8">
          <ReferenceId>17646408</ReferenceId>
          <FullCitation>Thompson BJ, et al. J. Exp. Med. (2007) pmid: 17646408</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="9">
          <ReferenceId>28481359</ReferenceId>
          <FullCitation>Zehir A, et al. Nat. Med. (2017) pmid: 28481359</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="10">
          <ReferenceId>23636398</ReferenceId>
          <FullCitation>Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="11">
          <ReferenceId>30068706</ReferenceId>
          <FullCitation>Soumerai TE, et al. Clin. Cancer Res. (2018) pmid: 30068706</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="12">
          <ReferenceId>23219661</ReferenceId>
          <FullCitation>Garcia-Dios DA, et al. Gynecol. Oncol. (2013) pmid: 23219661</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="13">
          <ReferenceId>22548670</ReferenceId>
          <FullCitation>Tu K, et al. Hepatol. Res. (2012) pmid: 22548670</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="14">
          <ReferenceId>19739118</ReferenceId>
          <FullCitation>Iwatsuki M, et al. Int. J. Cancer (2010) pmid: 19739118</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="15">
          <ReferenceId>22576686</ReferenceId>
          <FullCitation>Yokobori T, et al. Int. J. Oncol. (2012) pmid: 22576686</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="16">
          <ReferenceId>19366810</ReferenceId>
          <FullCitation>Yokobori T, et al. Cancer Res. (2009) pmid: 19366810</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="17">
          <ReferenceId>24165483</ReferenceId>
          <FullCitation>Yokobori T, et al. Mol. Cancer Res. (2014) pmid: 24165483</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="18">
          <ReferenceId>14999283</ReferenceId>
          <FullCitation>Rajagopalan H, et al. Nature (2004) pmid: 14999283</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="19">
          <ReferenceId>23381582</ReferenceId>
          <FullCitation>Cheng Y, et al. J. Invest. Dermatol. (2013) pmid: 23381582</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="20">
          <ReferenceId>26954701</ReferenceId>
          <FullCitation>Xu Y, et al. Biomarkers (2016) pmid: 26954701</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="21">
          <ReferenceId>25622249</ReferenceId>
          <FullCitation>Li Z, et al. Int J Mol Sci (2015) pmid: 25622249</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="22">
          <ReferenceId>18787170</ReferenceId>
          <FullCitation>Mao JH, et al. Science (2008) pmid: 18787170</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="23">
          <ReferenceId>25749036</ReferenceId>
          <FullCitation>Yang H, et al. Oncotarget (2015) pmid: 25749036</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="24">
          <ReferenceId>18483217</ReferenceId>
          <FullCitation>Andrae J, et al. Genes Dev. (2008) pmid: 18483217</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="25">
          <ReferenceId>15175998</ReferenceId>
          <FullCitation>Semin. Oncol. (2004) pmid: 15175998</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="26">
          <ReferenceId>23990986</ReferenceId>
          <FullCitation>Burford A, et al. PLoS ONE (2013) pmid: 23990986</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="27">
          <ReferenceId>26700815</ReferenceId>
          <FullCitation>Flavahan WA, et al. Nature (2016) pmid: 26700815</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="28">
          <ReferenceId>26787600</ReferenceId>
          <FullCitation>Roszik J, et al. Sci Rep (2016) pmid: 26787600</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="29">
          <ReferenceId>20129251</ReferenceId>
          <FullCitation>Verhaak RG, et al. Cancer Cell (2010) pmid: 20129251</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="30">
          <ReferenceId>27582545</ReferenceId>
          <FullCitation>Koschmann C, et al. Oncotarget (2016) pmid: 27582545</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="31">
          <ReferenceId>23438035</ReferenceId>
          <FullCitation>Phillips JJ, et al. Brain Pathol. (2013) pmid: 23438035</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="32">
          <ReferenceId>22389665</ReferenceId>
          <FullCitation>Puget S, et al. PLoS ONE (2012) pmid: 22389665</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="33">
          <ReferenceId>15385107</ReferenceId>
          <FullCitation>Slomovitz BM, et al. Gynecol. Oncol. (2004) pmid: 15385107</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="34">
          <ReferenceId>27051816</ReferenceId>
          <FullCitation>Frenard C, et al. JAAD Case Rep (2016) pmid: 27051816</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="35">
          <ReferenceId>19362466</ReferenceId>
          <FullCitation>Geoerger B, et al. Eur J Cancer (2009) pmid: 19362466</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="36">
          <ReferenceId>10582339</ReferenceId>
          <FullCitation>Int. J. Biochem. Cell Biol. (1999) pmid: 10582339</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="37">
          <ReferenceId>23550210</ReferenceId>
          <FullCitation>Gao J, et al. Sci Signal (2013) pmid: 23550210</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="38">
          <ReferenceId>24071852</ReferenceId>
          <FullCitation>Zack TI, et al. Nat. Genet. (2013) pmid: 24071852</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="39">
          <ReferenceId>20164920</ReferenceId>
          <FullCitation>Beroukhim R, et al. Nature (2010) pmid: 20164920</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="40">
          <ReferenceId>35120664</ReferenceId>
          <FullCitation>Nguyen B, et al. Cell (2022) pmid: 35120664</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="41">
          <ReferenceId>12649669</ReferenceId>
          <FullCitation>Scobie JV, et al. Int. J. Gynecol. Pathol. (2003) pmid: 12649669</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="42">
          <ReferenceId>29093181</ReferenceId>
          <FullCitation>Evans EK, et al. Sci Transl Med (2017) pmid: 29093181</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="43">
          <ReferenceId>27536065</ReferenceId>
          <FullCitation>Abbaspour Babaei M, et al. Drug Des Devel Ther (2016) pmid: 27536065</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="44">
          <ReferenceId>27563456</ReferenceId>
          <FullCitation>Ramaswamy A, et al. J Gastrointest Oncol (2016) pmid: 27563456</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="45">
          <ReferenceId>23177515</ReferenceId>
          <FullCitation>Demetri GD, et al. Lancet (2013) pmid: 23177515</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="46">
          <ReferenceId>27355533</ReferenceId>
          <FullCitation>Gotlib J, et al. N. Engl. J. Med. (2016) pmid: 27355533</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="47">
          <ReferenceId>28424161</ReferenceId>
          <FullCitation>Jawhar M, et al. Blood (2017) pmid: 28424161</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="48">
          <ReferenceId>25031773</ReferenceId>
          <FullCitation>Xu X, et al. Int J Clin Exp Pathol (2014) pmid: 25031773</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="49">
          <ReferenceId>15972446</ReferenceId>
          <FullCitation>Gotlib J, et al. Blood (2005) pmid: 15972446</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="50">
          <ReferenceId>29066909</ReferenceId>
          <FullCitation>Luo C, et al. Onco Targets Ther (2017) pmid: 29066909</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="51">
          <ReferenceId>35753087</ReferenceId>
          <FullCitation>Janku F, et al. ESMO Open (2022) pmid: 35753087</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="52">
          <ReferenceId>22162580</ReferenceId>
          <FullCitation>Si L, et al. J. Clin. Oncol. (2012) pmid: 22162580</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="53">
          <ReferenceId>20038218</ReferenceId>
          <FullCitation>Parikh SA, et al. Leuk Lymphoma (2010) pmid: 20038218</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="54">
          <ReferenceId>30075827</ReferenceId>
          <FullCitation>Wei X, et al. Oncol. Res. (2019) pmid: 30075827</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="55">
          <ReferenceId>23775962</ReferenceId>
          <FullCitation>Hodi FS, et al. J. Clin. Oncol. (2013) pmid: 23775962</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="56">
          <ReferenceId>21642685</ReferenceId>
          <FullCitation>Carvajal RD, et al. JAMA (2011) pmid: 21642685</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="57">
          <ReferenceId>21690468</ReferenceId>
          <FullCitation>Guo J, et al. J. Clin. Oncol. (2011) pmid: 21690468</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="58">
          <ReferenceId>15685537</ReferenceId>
          <FullCitation>Debiec-Rychter M, et al. Gastroenterology (2005) pmid: 15685537</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="59">
          <ReferenceId>19303137</ReferenceId>
          <FullCitation>Dematteo RP, et al. Lancet (2009) pmid: 19303137</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="60">
          <ReferenceId>16135502</ReferenceId>
          <FullCitation>Faivre S, et al. J. Clin. Oncol. (2005) pmid: 16135502</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="61">
          <ReferenceId>15659505</ReferenceId>
          <FullCitation>Hotte SJ, et al. J. Clin. Oncol. (2005) pmid: 15659505</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="62">
          <ReferenceId>15350030</ReferenceId>
          <FullCitation>Alcedo JC, et al. Head Neck (2004) pmid: 15350030</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="63">
          <ReferenceId>21403650</ReferenceId>
          <FullCitation>Brandwein JM, et al. Leukemia (2011) pmid: 21403650</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="64">
          <ReferenceId>19904263</ReferenceId>
          <FullCitation>Reardon DA, et al. Br. J. Cancer (2009) pmid: 19904263</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="65">
          <ReferenceId>26424760</ReferenceId>
          <FullCitation>Lee SJ, et al. Oncologist (2015) pmid: 26424760</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="66">
          <ReferenceId>22374331</ReferenceId>
          <FullCitation>Llovet JM, et al. Clin. Cancer Res. (2012) pmid: 22374331</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="67">
          <ReferenceId>23058498</ReferenceId>
          <FullCitation>Zhang HL, et al. Clin Genitourin Cancer (2013) pmid: 23058498</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="68">
          <ReferenceId>25450081</ReferenceId>
          <FullCitation>Seino S, et al. Gastroenterology (2014) pmid: 25450081</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="69">
          <ReferenceId>18846437</ReferenceId>
          <FullCitation>Li XF, et al. Med. Oncol. (2009) pmid: 18846437</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="70">
          <ReferenceId>22261812</ReferenceId>
          <FullCitation>Minor DR, et al. Clin. Cancer Res. (2012) pmid: 22261812</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="71">
          <ReferenceId>23114504</ReferenceId>
          <FullCitation>Mahipal A, et al. Melanoma Res. (2012) pmid: 23114504</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="72">
          <ReferenceId>16904903</ReferenceId>
          <FullCitation>Dang CV, et al. Semin. Cancer Biol. (2006) pmid: 16904903</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="73">
          <ReferenceId>10378696</ReferenceId>
          <FullCitation>Nesbit CE, et al. Oncogene (1999) pmid: 10378696</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="74">
          <ReferenceId>15083194</ReferenceId>
          <FullCitation>Blancato J, et al. Br. J. Cancer (2004) pmid: 15083194</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="75">
          <ReferenceId>23574779</ReferenceId>
          <FullCitation>Fromont G, et al. Hum. Pathol. (2013) pmid: 23574779</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="76">
          <ReferenceId>14663583</ReferenceId>
          <FullCitation>Konopka B, et al. J. Cancer Res. Clin. Oncol. (2004) pmid: 14663583</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="77">
          <ReferenceId>10600396</ReferenceId>
          <FullCitation>Williams JA, et al. Exp. Mol. Pathol. (1999) pmid: 10600396</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="78">
          <ReferenceId>10473073</ReferenceId>
          <FullCitation>Schraml P, et al. Clin. Cancer Res. (1999) pmid: 10473073</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="79">
          <ReferenceId>7977518</ReferenceId>
          <FullCitation>Monk BJ, et al. Am. J. Obstet. Gynecol. (1994) pmid: 7977518</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="80">
          <ReferenceId>22430491</ReferenceId>
          <FullCitation>Horiuchi D, et al. J. Exp. Med. (2012) pmid: 22430491</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="81">
          <ReferenceId>17589519</ReferenceId>
          <FullCitation>Goga A, et al. Nat. Med. (2007) pmid: 17589519</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="82">
          <ReferenceId>19525400</ReferenceId>
          <FullCitation>Molenaar JJ, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19525400</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="83">
          <ReferenceId>31375684</ReferenceId>
          <FullCitation>Dammert MA, et al. Nat Commun (2019) pmid: 31375684</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="84">
          <ReferenceId>28089889</ReferenceId>
          <FullCitation>Mollaoglu G, et al. Cancer Cell (2017) pmid: 28089889</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="85">
          <ReferenceId>29088717</ReferenceId>
          <FullCitation>Cardnell RJ, et al. Oncotarget (2017) pmid: 29088717</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="86">
          <ReferenceId>28417568</ReferenceId>
          <FullCitation>Wang L, et al. Mol Oncol (2017) pmid: 28417568</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="87">
          <ReferenceId>25632068</ReferenceId>
          <FullCitation>Takahashi Y, et al. Ann. Oncol. (2015) pmid: 25632068</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="88">
          <ReferenceId>30226440</ReferenceId>
          <FullCitation>Li Y, et al. Thyroid (2018) pmid: 30226440</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="89">
          <ReferenceId>24893165</ReferenceId>
          <FullCitation>Mahadevan D, et al. PLoS ONE (2014) pmid: 24893165</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="90">
          <ReferenceId>31429028</ReferenceId>
          <FullCitation>Park SI, et al. Target Oncol (2019) pmid: 31429028</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="91">
          <ReferenceId>27496133</ReferenceId>
          <FullCitation>Helfrich BA, et al. Mol. Cancer Ther. (2016) pmid: 27496133</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="92">
          <ReferenceId>22222631</ReferenceId>
          <FullCitation>Hook KE, et al. Mol. Cancer Ther. (2012) pmid: 22222631</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="93">
          <ReferenceId>20643922</ReferenceId>
          <FullCitation>Yang D, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20643922</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="94">
          <ReferenceId>30540594</ReferenceId>
          <FullCitation>He J, et al. Anticancer Drugs (2019) pmid: 30540594</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="95">
          <ReferenceId>25964345</ReferenceId>
          <FullCitation>Shroff EH, et al. Proc. Natl. Acad. Sci. U.S.A. (2015) pmid: 25964345</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="96">
          <ReferenceId>29156762</ReferenceId>
          <FullCitation>Effenberger M, et al. Oncotarget (2017) pmid: 29156762</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="97">
          <ReferenceId>30103944</ReferenceId>
          <FullCitation>Qu X, et al. Biochem. Biophys. Res. Commun. (2018) pmid: 30103944</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="98">
          <ReferenceId>25915584</ReferenceId>
          <FullCitation>Xiang Y, et al. J. Clin. Invest. (2015) pmid: 25915584</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="99">
          <ReferenceId>21889194</ReferenceId>
          <FullCitation>Delmore JE, et al. Cell (2011) pmid: 21889194</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="100">
          <ReferenceId>24297863</ReferenceId>
          <FullCitation>Bandopadhayay P, et al. Clin. Cancer Res. (2014) pmid: 24297863</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="101">
          <ReferenceId>23582323</ReferenceId>
          <FullCitation>Lovén J, et al. Cell (2013) pmid: 23582323</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="102">
          <ReferenceId>31734632</ReferenceId>
          <FullCitation>Otto C, et al. Neoplasia (2019) pmid: 31734632</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="103">
          <ReferenceId>23866964</ReferenceId>
          <FullCitation>Dong LH, et al. J Hematol Oncol (2013) pmid: 23866964</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="104">
          <ReferenceId>26977882</ReferenceId>
          <FullCitation>Pei Y, et al. Cancer Cell (2016) pmid: 26977882</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="105">
          <ReferenceId>30224636</ReferenceId>
          <FullCitation>Fu XH, et al. Acta Pharmacol. Sin. (2019) pmid: 30224636</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="106">
          <ReferenceId>31655296</ReferenceId>
          <FullCitation>Owonikoko TK, et al. J Thorac Oncol (2020) pmid: 31655296</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="107">
          <ReferenceId>25253784</ReferenceId>
          <FullCitation>Ganesan P, et al. Mol. Cancer Ther. (2014) pmid: 25253784</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="108">
          <ReferenceId>23555992</ReferenceId>
          <FullCitation>Pereira CB, et al. PLoS ONE (2013) pmid: 23555992</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="109">
          <ReferenceId>21741827</ReferenceId>
          <FullCitation>Yasojima H, et al. Eur. J. Cancer (2011) pmid: 21741827</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="110">
          <ReferenceId>11406570</ReferenceId>
          <FullCitation>Arango D, et al. Cancer Res. (2001) pmid: 11406570</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="111">
          <ReferenceId>14516787</ReferenceId>
          <FullCitation>Bottone MG, et al. Exp. Cell Res. (2003) pmid: 14516787</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="112">
          <ReferenceId>16337594</ReferenceId>
          <FullCitation>Sdek P, et al. Mol. Cell (2005) pmid: 16337594</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="113">
          <ReferenceId>15632057</ReferenceId>
          <FullCitation>Brady M, et al. Mol. Cell. Biol. (2005) pmid: 15632057</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="114">
          <ReferenceId>15053880</ReferenceId>
          <FullCitation>Li M, et al. Mol. Cell (2004) pmid: 15053880</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="115">
          <ReferenceId>19935675</ReferenceId>
          <FullCitation>Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="116">
          <ReferenceId>8306343</ReferenceId>
          <FullCitation>Cordon-Cardo C, et al. Cancer Res. (1994) pmid: 8306343</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="117">
          <ReferenceId>28511869</ReferenceId>
          <FullCitation>Edmondson RJ, et al. Gynecol. Oncol. (2017) pmid: 28511869</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="118">
          <ReferenceId>8972476</ReferenceId>
          <FullCitation>Ambros RA, et al. Mod. Pathol. (1996) pmid: 8972476</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="119">
          <ReferenceId>20975744</ReferenceId>
          <FullCitation>Cheok CF, et al. Nat Rev Clin Oncol (2011) pmid: 20975744</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="120">
          <ReferenceId>23165797</ReferenceId>
          <FullCitation>Ohnstad HO, et al. Cancer (2013) pmid: 23165797</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="121">
          <ReferenceId>21725357</ReferenceId>
          <FullCitation>Gamble LD, et al. Oncogene (2012) pmid: 21725357</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="122">
          <ReferenceId>15147722</ReferenceId>
          <FullCitation>Möröy T, et al. Int. J. Biochem. Cell Biol. (2004) pmid: 15147722</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="123">
          <ReferenceId>16575401</ReferenceId>
          <FullCitation>Leung SY, et al. Mod. Pathol. (2006) pmid: 16575401</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="124">
          <ReferenceId>11156406</ReferenceId>
          <FullCitation>Lin L, et al. Cancer Res. (2000) pmid: 11156406</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="125">
          <ReferenceId>16753589</ReferenceId>
          <FullCitation>Mayr D, et al. Am. J. Clin. Pathol. (2006) pmid: 16753589</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="126">
          <ReferenceId>20336784</ReferenceId>
          <FullCitation>Nakayama N, et al. Cancer (2010) pmid: 20336784</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="127">
          <ReferenceId>21176227</ReferenceId>
          <FullCitation>Stamatakos M, et al. World J Surg Oncol (2010) pmid: 21176227</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="128">
          <ReferenceId>24309323</ReferenceId>
          <FullCitation>Kuhn E, et al. Mod. Pathol. (2014) pmid: 24309323</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="129">
          <ReferenceId>12432043</ReferenceId>
          <FullCitation>Keyomarsi K, et al. N. Engl. J. Med. (2002) pmid: 12432043</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="130">
          <ReferenceId>19179977</ReferenceId>
          <FullCitation>Potemski P, et al. Med. Sci. Monit. (2009) pmid: 19179977</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="131">
          <ReferenceId>15682439</ReferenceId>
          <FullCitation>Callagy G, et al. J. Pathol. (2005) pmid: 15682439</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="132">
          <ReferenceId>28331049</ReferenceId>
          <FullCitation>Lin AB, et al. Clin. Cancer Res. (2017) pmid: 28331049</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="133">
          <ReferenceId>30181387</ReferenceId>
          <FullCitation>Chen X, et al. Clin Cancer Res (2018) pmid: 30181387</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="134">
          <ReferenceId>29361470</ReferenceId>
          <FullCitation>Lee JM, et al. Lancet Oncol. (2018) pmid: 29361470</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="135">
          <ReferenceId>33485453</ReferenceId>
          <FullCitation>Lheureux S, et al. Lancet (2021) pmid: 33485453</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="136">
          <ReferenceId>32611648</ReferenceId>
          <FullCitation>Oza AM, et al. Clin Cancer Res (2020) pmid: 32611648</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="137">
          <ReferenceId>36469840</ReferenceId>
          <FullCitation>Fu S, et al. J Clin Oncol (2023) pmid: 36469840</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="138">
          <ReferenceId>23686769</ReferenceId>
          <FullCitation>Ma T, et al. Mol. Cancer Ther. (2013) pmid: 23686769</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="139">
          <ReferenceId>21552262</ReferenceId>
          <FullCitation>Toledo LI, et al. Nat. Struct. Mol. Biol. (2011) pmid: 21552262</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="140">
          <ReferenceId>26365377</ReferenceId>
          <FullCitation>Buisson R, et al. Mol. Cell (2015) pmid: 26365377</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="141">
          <ReferenceId>26204491</ReferenceId>
          <FullCitation>Yang L, et al. Oncotarget (2015) pmid: 26204491</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="142">
          <ReferenceId>35444283</ReferenceId>
          <FullCitation>Gallo D, et al. Nature (2022) pmid: 35444283</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="143">
          <ReferenceId>35880755</ReferenceId>
          <FullCitation>Szychowski J, et al. J Med Chem (2022) pmid: 35880755</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="144">
          <ReferenceId>33028815</ReferenceId>
          <FullCitation>Kok YP, et al. Oncogenesis (2020) pmid: 33028815</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="145">
          <ReferenceId>25557169</ReferenceId>
          <FullCitation>Taylor-Harding B, et al. Oncotarget (2015) pmid: 25557169</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="146">
          <ReferenceId>24004674</ReferenceId>
          <FullCitation>Etemadmoghadam D, et al. Clin. Cancer Res. (2013) pmid: 24004674</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="147">
          <ReferenceId>21321214</ReferenceId>
          <FullCitation>Scaltriti M, et al. Proc. Natl. Acad. Sci. U.S.A. (2011) pmid: 21321214</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="148">
          <ReferenceId>21695458</ReferenceId>
          <FullCitation>Nanos-Webb A, et al. Breast Cancer Res. Treat. (2012) pmid: 21695458</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="149">
          <ReferenceId>26337942</ReferenceId>
          <FullCitation>Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="150">
          <ReferenceId>21081928</ReferenceId>
          <FullCitation>You JF, et al. Br. J. Cancer (2010) pmid: 21081928</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="151">
          <ReferenceId>24623249</ReferenceId>
          <FullCitation>Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="152">
          <ReferenceId>9823339</ReferenceId>
          <FullCitation>Boland CR, et al. Cancer Res. (1998) pmid: 9823339</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="153">
          <ReferenceId>15528785</ReferenceId>
          <FullCitation>Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="154">
          <ReferenceId>20420947</ReferenceId>
          <FullCitation>Boland CR, et al. Gastroenterology (2010) pmid: 20420947</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="155">
          <ReferenceId>16549821</ReferenceId>
          <FullCitation>Black D, et al. J. Clin. Oncol. (2006) pmid: 16549821</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="156">
          <ReferenceId>20304627</ReferenceId>
          <FullCitation>Mackay HJ, et al. Eur. J. Cancer (2010) pmid: 20304627</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="157">
          <ReferenceId>25458958</ReferenceId>
          <FullCitation>Kanopienė D, et al. Medicina (Kaunas) (2014) pmid: 25458958</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="158">
          <ReferenceId>16885385</ReferenceId>
          <FullCitation>Hampel H, et al. Cancer Res. (2006) pmid: 16885385</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="159">
          <ReferenceId>21547578</ReferenceId>
          <FullCitation>Steinbakk A, et al. Cell Oncol (Dordr) (2011) pmid: 21547578</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="160">
          <ReferenceId>20005452</ReferenceId>
          <FullCitation>Bilbao C, et al. Int. J. Radiat. Oncol. Biol. Phys. (2010) pmid: 20005452</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="161">
          <ReferenceId>23528559</ReferenceId>
          <FullCitation>Church DN, et al. Hum. Mol. Genet. (2013) pmid: 23528559</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="162">
          <ReferenceId>34996131</ReferenceId>
          <FullCitation>McCluggage WG, et al. Histopathology (2022) pmid: 34996131</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="163">
          <ReferenceId>35690222</ReferenceId>
          <FullCitation>Oaknin A, et al. Ann Oncol (2022) pmid: 35690222</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="164">
          <ReferenceId>26172027</ReferenceId>
          <FullCitation>Talhouk A, et al. Br J Cancer (2015) pmid: 26172027</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="165">
          <ReferenceId>33604759</ReferenceId>
          <FullCitation>Concin N, et al. Virchows Arch (2021) pmid: 33604759</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="166">
          <ReferenceId>36357827</ReferenceId>
          <FullCitation>Wu Q, et al. BMC Cancer (2022) pmid: 36357827</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="167">
          <ReferenceId>35658479</ReferenceId>
          <FullCitation>Thiel KW, et al. J Clin Oncol (2022) pmid: 35658479</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="168">
          <ReferenceId>36857998</ReferenceId>
          <FullCitation>Irshaid L, et al. Mod Pathol (2023) pmid: 36857998</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="169">
          <ReferenceId>35078648</ReferenceId>
          <FullCitation>Leon-Castillo A, et al. Gynecol Oncol (2022) pmid: 35078648</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="170">
          <ReferenceId>32749941</ReferenceId>
          <FullCitation>León-Castillo A, et al. J Clin Oncol (2020) pmid: 32749941</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="171">
          <ReferenceId>37337978</ReferenceId>
          <FullCitation>Berek JS, et al. Int J Gynaecol Obstet (2023) pmid: 37337978</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="172">
          <ReferenceId>17513808</ReferenceId>
          <FullCitation>Zighelboim I, et al. J. Clin. Oncol. (2007) pmid: 17513808</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="173">
          <ReferenceId>25026289</ReferenceId>
          <FullCitation>Bilbao-Sieyro C, et al. Oncotarget (2014) pmid: 25026289</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="174">
          <ReferenceId>19275958</ReferenceId>
          <FullCitation>Arabi H, et al. Gynecol. Oncol. (2009) pmid: 19275958</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="175">
          <ReferenceId>27006490</ReferenceId>
          <FullCitation>Stelloo E, et al. Clin. Cancer Res. (2016) pmid: 27006490</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="176">
          <ReferenceId>22609107</ReferenceId>
          <FullCitation>Nout RA, et al. Gynecol. Oncol. (2012) pmid: 22609107</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="177">
          <ReferenceId>25392179</ReferenceId>
          <FullCitation>Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="178">
          <ReferenceId>26140250</ReferenceId>
          <FullCitation>Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="179">
          <ReferenceId>25949894</ReferenceId>
          <FullCitation>Lal N, et al. Oncoimmunology (2015) pmid: 25949894</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="180">
          <ReferenceId>26028255</ReferenceId>
          <FullCitation>Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="181">
          <ReferenceId>24957944</ReferenceId>
          <FullCitation>Holderfield M, et al. Nat. Rev. Cancer (2014) pmid: 24957944</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="182">
          <ReferenceId>24948110</ReferenceId>
          <FullCitation>Burotto M, et al. Cancer (2014) pmid: 24948110</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="183">
          <ReferenceId>12068308</ReferenceId>
          <FullCitation>Davies H, et al. Nature (2002) pmid: 12068308</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="184">
          <ReferenceId>24132290</ReferenceId>
          <FullCitation>Kandoth C, et al. Nature (2013) pmid: 24132290</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="185">
          <ReferenceId>15035987</ReferenceId>
          <FullCitation>Wan PT, et al. Cell (2004) pmid: 15035987</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="186">
          <ReferenceId>28947956</ReferenceId>
          <FullCitation>Noeparast A, et al. Oncotarget (2017) pmid: 28947956</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="187">
          <ReferenceId>18794803</ReferenceId>
          <FullCitation>Smalley KS, et al. Oncogene (2009) pmid: 18794803</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="188">
          <ReferenceId>19351826</ReferenceId>
          <FullCitation>Smalley KS, et al. Cancer Res. (2009) pmid: 19351826</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="189">
          <ReferenceId>15150094</ReferenceId>
          <FullCitation>Ikenoue T, et al. Cancer Res. (2004) pmid: 15150094</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="190">
          <ReferenceId>22649091</ReferenceId>
          <FullCitation>Sen B, et al. Sci Transl Med (2012) pmid: 22649091</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="191">
          <ReferenceId>20978199</ReferenceId>
          <FullCitation>Kamata T, et al. Cancer Res. (2010) pmid: 20978199</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="192">
          <ReferenceId>23833300</ReferenceId>
          <FullCitation>Cardarella S, et al. Clin. Cancer Res. (2013) pmid: 23833300</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="193">
          <ReferenceId>16474404</ReferenceId>
          <FullCitation>Niihori T, et al. Nat. Genet. (2006) pmid: 16474404</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="194">
          <ReferenceId>19735675</ReferenceId>
          <FullCitation>Moretti S, et al. Biochim. Biophys. Acta (2009) pmid: 19735675</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="195">
          <ReferenceId>18413255</ReferenceId>
          <FullCitation>Rodriguez-Viciana P, et al. Meth. Enzymol. (2008) pmid: 18413255</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="196">
          <ReferenceId>22301711</ReferenceId>
          <FullCitation>Anastasaki C, et al. Dis Model Mech (2012) pmid: 22301711</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="197">
          <ReferenceId>28783719</ReferenceId>
          <FullCitation>Yao Z, et al. Nature (2017) pmid: 28783719</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="198">
          <ReferenceId>32913992</ReferenceId>
          <FullCitation>Sheikine Y, et al. JCO Precis Oncol (2018) pmid: 32913992</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="199">
          <ReferenceId>16364920</ReferenceId>
          <FullCitation>Garnett MJ, et al. Mol. Cell (2005) pmid: 16364920</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="200">
          <ReferenceId>17388789</ReferenceId>
          <FullCitation>Mizumoto Y, et al. Cancer Sci. (2007) pmid: 17388789</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="201">
          <ReferenceId>16256179</ReferenceId>
          <FullCitation>Pappa KI, et al. Gynecol. Oncol. (2006) pmid: 16256179</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="202">
          <ReferenceId>15118616</ReferenceId>
          <FullCitation>Mutch DG, et al. Am. J. Obstet. Gynecol. (2004) pmid: 15118616</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="203">
          <ReferenceId>15723290</ReferenceId>
          <FullCitation>Salvesen HB, et al. Int. J. Cancer (2005) pmid: 15723290</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="204">
          <ReferenceId>16144912</ReferenceId>
          <FullCitation>Feng YZ, et al. Clin. Cancer Res. (2005) pmid: 16144912</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="205">
          <ReferenceId>23370429</ReferenceId>
          <FullCitation>He M, et al. Diagn. Mol. Pathol. (2013) pmid: 23370429</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="206">
          <ReferenceId>31924734</ReferenceId>
          <FullCitation>Johnson DB, et al. Clin Cancer Res (2020) pmid: 31924734</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="207">
          <ReferenceId>33722853</ReferenceId>
          <FullCitation>Nikanjam M, et al. Mol Cancer Ther (2021) pmid: 33722853</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="208">
          <ReferenceId>33861486</ReferenceId>
          <FullCitation>Nebhan CA, et al. Oncologist (2021) pmid: 33861486</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="209">
          <ReferenceId>27911979</ReferenceId>
          <FullCitation>Kim DW, et al. Cancer (2017) pmid: 27911979</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="210">
          <ReferenceId>31959346</ReferenceId>
          <FullCitation>Mazieres J, et al. Ann. Oncol. (2020) pmid: 31959346</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="211">
          <ReferenceId>29320312</ReferenceId>
          <FullCitation>Hainsworth JD, et al. J. Clin. Oncol. (2018) pmid: 29320312</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="212">
          <ReferenceId>29247021</ReferenceId>
          <FullCitation>Sullivan RJ, et al. Cancer Discov (2018) pmid: 29247021</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="213">
          <ReferenceId>26182352</ReferenceId>
          <FullCitation>Clark AD, et al. Crit. Rev. Biochem. Mol. Biol. (2015) pmid: 26182352</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="214">
          <ReferenceId>18691967</ReferenceId>
          <FullCitation>Ding N, et al. Mol. Cell (2008) pmid: 18691967</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="215">
          <ReferenceId>16565090</ReferenceId>
          <FullCitation>Kim S, et al. J. Biol. Chem. (2006) pmid: 16565090</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="216">
          <ReferenceId>26383637</ReferenceId>
          <FullCitation>Kämpjärvi K, et al. Prostate (2016) pmid: 26383637</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="217">
          <ReferenceId>17000779</ReferenceId>
          <FullCitation>Zhou H, et al. Mol. Cell. Biol. (2006) pmid: 17000779</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="218">
          <ReferenceId>23178117</ReferenceId>
          <FullCitation>Huang S, et al. Cell (2012) pmid: 23178117</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="219">
          <ReferenceId>24938407</ReferenceId>
          <FullCitation>Shaikhibrahim Z, et al. Endocr. Relat. Cancer (2014) pmid: 24938407</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="220">
          <ReferenceId>24746821</ReferenceId>
          <FullCitation>Turunen M, et al. Cell Rep (2014) pmid: 24746821</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="221">
          <ReferenceId>24980722</ReferenceId>
          <FullCitation>Kämpjärvi K, et al. Hum. Mutat. (2014) pmid: 24980722</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="222">
          <ReferenceId>21868628</ReferenceId>
          <FullCitation>Mäkinen N, et al. Science (2011) pmid: 21868628</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="223">
          <ReferenceId>23913526</ReferenceId>
          <FullCitation>Mäkinen N, et al. Int. J. Cancer (2014) pmid: 23913526</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="224">
          <ReferenceId>26018969</ReferenceId>
          <FullCitation>Ng CC, et al. J. Clin. Pathol. (2015) pmid: 26018969</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="225">
          <ReferenceId>27187686</ReferenceId>
          <FullCitation>Kämpjärvi K, et al. Br. J. Cancer (2016) pmid: 27187686</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="226">
          <ReferenceId>26396919</ReferenceId>
          <FullCitation>Shahbazi S, et al. Am J Cancer Res (2015) pmid: 26396919</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="227">
          <ReferenceId>25325994</ReferenceId>
          <FullCitation>Halder SK, et al. Mol. Genet. Genomics (2015) pmid: 25325994</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="228">
          <ReferenceId>25272295</ReferenceId>
          <FullCitation>Markowski DN, et al. Int. J. Gynecol. Pathol. (2014) pmid: 25272295</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="229">
          <ReferenceId>26832993</ReferenceId>
          <FullCitation>Piscuoglio S, et al. J. Pathol. (2016) pmid: 26832993</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="230">
          <ReferenceId>26093648</ReferenceId>
          <FullCitation>Mishima C, et al. Breast Cancer Res. Treat. (2015) pmid: 26093648</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="231">
          <ReferenceId>26637855</ReferenceId>
          <FullCitation>Holzmann C, et al. Anticancer Res. (2015) pmid: 26637855</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="232">
          <ReferenceId>22768200</ReferenceId>
          <FullCitation>Pérot G, et al. PLoS ONE (2012) pmid: 22768200</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="233">
          <ReferenceId>26860948</ReferenceId>
          <FullCitation>Lien HC, et al. APMIS (2016) pmid: 26860948</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="234">
          <ReferenceId>25593300</ReferenceId>
          <FullCitation>Cani AK, et al. Mol. Cancer Res. (2015) pmid: 25593300</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="235">
          <ReferenceId>25038752</ReferenceId>
          <FullCitation>Lim WK, et al. Nat. Genet. (2014) pmid: 25038752</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="236">
          <ReferenceId>26037152</ReferenceId>
          <FullCitation>Croce S, et al. Eur. J. Cancer (2015) pmid: 26037152</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="237">
          <ReferenceId>23222489</ReferenceId>
          <FullCitation>Ravegnini G, et al. Mod. Pathol. (2013) pmid: 23222489</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="238">
          <ReferenceId>26316624</ReferenceId>
          <FullCitation>Guièze R, et al. Blood (2015) pmid: 26316624</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="239">
          <ReferenceId>25595892</ReferenceId>
          <FullCitation>Kämpjärvi K, et al. Oncotarget (2015) pmid: 25595892</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="240">
          <ReferenceId>22610119</ReferenceId>
          <FullCitation>Barbieri CE, et al. Nat. Genet. (2012) pmid: 22610119</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="241">
          <ReferenceId>26924278</ReferenceId>
          <FullCitation>Yoon N, et al. Asian J. Androl. () pmid: 26924278</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="242">
          <ReferenceId>26856273</ReferenceId>
          <FullCitation>Yoon N, et al. Genes Chromosomes Cancer (2016) pmid: 26856273</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="243">
          <ReferenceId>25855048</ReferenceId>
          <FullCitation>Piscuoglio S, et al. Histopathology (2015) pmid: 25855048</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="244">
          <ReferenceId>25839987</ReferenceId>
          <FullCitation>Yoshida M, et al. Br. J. Cancer (2015) pmid: 25839987</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="245">
          <ReferenceId>26193636</ReferenceId>
          <FullCitation>Mittal P, et al. J. Clin. Invest. (2015) pmid: 26193636</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="246">
          <ReferenceId>25015674</ReferenceId>
          <FullCitation>Di Tommaso S, et al. Mol. Hum. Reprod. (2014) pmid: 25015674</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="247">
          <ReferenceId>27068464</ReferenceId>
          <FullCitation>Bhagwat AS, et al. Cell Rep (2016) pmid: 27068464</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="248">
          <ReferenceId>15748635</ReferenceId>
          <FullCitation>Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="249">
          <ReferenceId>23875803</ReferenceId>
          <FullCitation>Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="250">
          <ReferenceId>12379884</ReferenceId>
          <FullCitation>Pfeifer GP, et al. Oncogene (2002) pmid: 12379884</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="251">
          <ReferenceId>25765070</ReferenceId>
          <FullCitation>Rizvi NA, et al. Science (2015) pmid: 25765070</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="252">
          <ReferenceId>24336570</ReferenceId>
          <FullCitation>Johnson BE, et al. Science (2014) pmid: 24336570</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="253">
          <ReferenceId>29452419</ReferenceId>
          <FullCitation>Choi S, et al. Neuro-oncology (2018) pmid: 29452419</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="254">
          <ReferenceId>23447401</ReferenceId>
          <FullCitation>Briggs S, et al. J. Pathol. (2013) pmid: 23447401</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="255">
          <ReferenceId>24583393</ReferenceId>
          <FullCitation>Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="256">
          <ReferenceId>22810696</ReferenceId>
          <FullCitation>Nature (2012) pmid: 22810696</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="257">
          <ReferenceId>25568919</ReferenceId>
          <FullCitation>Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="258">
          <ReferenceId>28835386</ReferenceId>
          <FullCitation>Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="259">
          <ReferenceId>32919526</ReferenceId>
          <FullCitation>Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="260">
          <ReferenceId>31405947</ReferenceId>
          <FullCitation>Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="261">
          <ReferenceId>28420421</ReferenceId>
          <FullCitation>Chalmers ZR, et al. Genome Med (2017) pmid: 28420421</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="262">
          <ReferenceId>27159395</ReferenceId>
          <FullCitation>Mehnert JM, et al. J. Clin. Invest. (2016) pmid: 27159395</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="263">
          <ReferenceId>25394778</ReferenceId>
          <FullCitation>Hussein YR, et al. Mod. Pathol. (2015) pmid: 25394778</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="264">
          <ReferenceId>33119110</ReferenceId>
          <FullCitation>Shao C, et al. JAMA Netw Open (2020) pmid: 33119110</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="265">
          <ReferenceId>30643254</ReferenceId>
          <FullCitation>Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="266">
          <ReferenceId>30309915</ReferenceId>
          <FullCitation>Cristescu R, et al. Science (2018) pmid: 30309915</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="267">
          <ReferenceId>30785829</ReferenceId>
          <FullCitation>Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="268">
          <ReferenceId>29658845</ReferenceId>
          <FullCitation>Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="269">
          <ReferenceId>29657128</ReferenceId>
          <FullCitation>Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="270">
          <ReferenceId>29731394</ReferenceId>
          <FullCitation>Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="271">
          <ReferenceId>33558721</ReferenceId>
          <FullCitation>Rozeman EA, et al. Nat Med (2021) pmid: 33558721</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="272">
          <ReferenceId>32916128</ReferenceId>
          <FullCitation>Sharma P, et al. Cancer Cell (2020) pmid: 32916128</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="273">
          <ReferenceId>30557521</ReferenceId>
          <FullCitation>Ott PA, et al. J. Clin. Oncol. (2019) pmid: 30557521</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="274">
          <ReferenceId>35101941</ReferenceId>
          <FullCitation>Cristescu R, et al. J Immunother Cancer (2022) pmid: 35101941</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="275">
          <ReferenceId>34876409</ReferenceId>
          <FullCitation>Friedman CF, et al. Cancer Discov (2022) pmid: 34876409</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="276">
          <ReferenceId>35274716</ReferenceId>
          <FullCitation>Sturgill EG, et al. Oncologist (2022) pmid: 35274716</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="277">
          <ReferenceId>24508459</ReferenceId>
          <FullCitation>An J, et al. Cell Rep (2014) pmid: 24508459</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="278">
          <ReferenceId>36693379</ReferenceId>
          <FullCitation>Cuneo MJ, et al. Mol Cell (2023) pmid: 36693379</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="279">
          <ReferenceId>36512624</ReferenceId>
          <FullCitation>Zhang H, et al. Cancer Res (2023) pmid: 36512624</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="280">
          <ReferenceId>25766326</ReferenceId>
          <FullCitation>Zhang P, et al. Cell Death Dis (2015) pmid: 25766326</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="281">
          <ReferenceId>32355326</ReferenceId>
          <FullCitation>Wang Z, et al. Nat Rev Urol (2020) pmid: 32355326</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="282">
          <ReferenceId>31901237</ReferenceId>
          <FullCitation>Song Y, et al. Mol Cancer (2020) pmid: 31901237</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="283">
          <ReferenceId>19818708</ReferenceId>
          <FullCitation>Zhuang M, et al. Mol. Cell (2009) pmid: 19818708</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="284">
          <ReferenceId>24563616</ReferenceId>
          <FullCitation>Blattner M, et al. Neoplasia (2014) pmid: 24563616</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="285">
          <ReferenceId>25058385</ReferenceId>
          <FullCitation>Drug Discov. Today (2014) pmid: 25058385</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="286">
          <ReferenceId>31026449</ReferenceId>
          <FullCitation>Ostertag MS, et al. J Mol Biol (2019) pmid: 31026449</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="287">
          <ReferenceId>34974131</ReferenceId>
          <FullCitation>Bernasocchi T, et al. Cancer Lett (2022) pmid: 34974131</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="288">
          <ReferenceId>23216165</ReferenceId>
          <FullCitation>Kim MS, et al. APMIS (2013) pmid: 23216165</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="289">
          <ReferenceId>30068710</ReferenceId>
          <FullCitation>Boysen G, et al. Clin Cancer Res (2018) pmid: 30068710</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="290">
          <ReferenceId>36088616</ReferenceId>
          <FullCitation>Swami U, et al. Clin Cancer Res (2022) pmid: 36088616</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="291">
          <ReferenceId>33849963</ReferenceId>
          <FullCitation>McKay RR, et al. Clin Cancer Res (2021) pmid: 33849963</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="292">
          <ReferenceId>31061129</ReferenceId>
          <FullCitation>Abida W, et al. Proc. Natl. Acad. Sci. U.S.A. (2019) pmid: 31061129</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="293">
          <ReferenceId>22130231</ReferenceId>
          <FullCitation>Biol. Pharm. Bull. (2011) pmid: 22130231</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="294">
          <ReferenceId>16557278</ReferenceId>
          <FullCitation>Giatromanolaki A, et al. Mod. Pathol. (2006) pmid: 16557278</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="295">
          <ReferenceId>15867479</ReferenceId>
          <FullCitation>Talvensaari-Mattila A, et al. Tumour Biol. () pmid: 15867479</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="296">
          <ReferenceId>20695190</ReferenceId>
          <FullCitation>Dobrzycka B, et al. Ginekol. Pol. (2010) pmid: 20695190</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="297">
          <ReferenceId>10831352</ReferenceId>
          <FullCitation>Yokoyama Y, et al. Gynecol. Oncol. (2000) pmid: 10831352</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="298">
          <ReferenceId>21208810</ReferenceId>
          <FullCitation>Koukourakis MI, et al. Cytokine (2011) pmid: 21208810</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="299">
          <ReferenceId>23273598</ReferenceId>
          <FullCitation>Piastowska-Ciesielska AW, et al. Cytokine (2013) pmid: 23273598</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="300">
          <ReferenceId>11908694</ReferenceId>
          <FullCitation>Anticancer Res. () pmid: 11908694</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="301">
          <ReferenceId>11745191</ReferenceId>
          <FullCitation>Giatromanolaki A, et al. Cancer (2001) pmid: 11745191</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="302">
          <ReferenceId>24420153</ReferenceId>
          <FullCitation>Saarelainen SK, et al. Tumour Biol. (2014) pmid: 24420153</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="303">
          <ReferenceId>32158235</ReferenceId>
          <FullCitation>Ma H, et al. Onco Targets Ther (2020) pmid: 32158235</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="304">
          <ReferenceId>29095068</ReferenceId>
          <FullCitation>Beuselinck B, et al. Acta Oncol (2018) pmid: 29095068</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="305">
          <ReferenceId>26228213</ReferenceId>
          <FullCitation>Song Y, et al. Chin. Med. J. (2015) pmid: 26228213</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="306">
          <ReferenceId>24086736</ReferenceId>
          <FullCitation>Dornbusch J, et al. PLoS ONE (2013) pmid: 24086736</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="307">
          <ReferenceId>21478036</ReferenceId>
          <FullCitation>Terakawa T, et al. Urol. Oncol. (2013) pmid: 21478036</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="308">
          <ReferenceId>24710685</ReferenceId>
          <FullCitation>You D, et al. World J Urol (2015) pmid: 24710685</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="309">
          <ReferenceId>25639617</ReferenceId>
          <FullCitation>Silva E, et al. Breast J () pmid: 25639617</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="310">
          <ReferenceId>33035615</ReferenceId>
          <FullCitation>Grillo E, et al. Cancer Lett (2021) pmid: 33035615</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="311">
          <ReferenceId>26627848</ReferenceId>
          <FullCitation>Baumgarten P, et al. Neuro-oncology (2016) pmid: 26627848</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="312">
          <ReferenceId>18182667</ReferenceId>
          <FullCitation>Sathornsumetee S, et al. J. Clin. Oncol. (2008) pmid: 18182667</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="313">
          <ReferenceId>31582283</ReferenceId>
          <FullCitation>Olafson LR, et al. J Clin Neurosci (2019) pmid: 31582283</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="314">
          <ReferenceId>20484123</ReferenceId>
          <FullCitation>Duda DG, et al. Oncologist (2010) pmid: 20484123</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="315">
          <ReferenceId>27535973</ReferenceId>
          <FullCitation>Stremitzer S, et al. Mol. Cancer Ther. (2016) pmid: 27535973</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="316">
          <ReferenceId>26125443</ReferenceId>
          <FullCitation>Weickhardt AJ, et al. Br. J. Cancer (2015) pmid: 26125443</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="317">
          <ReferenceId>20008624</ReferenceId>
          <FullCitation>Kopetz S, et al. J. Clin. Oncol. (2010) pmid: 20008624</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="318">
          <ReferenceId>23422754</ReferenceId>
          <FullCitation>Miles DW, et al. Br. J. Cancer (2013) pmid: 23422754</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="319">
          <ReferenceId>21868552</ReferenceId>
          <FullCitation>Fountzilas G, et al. Anticancer Res. (2011) pmid: 21868552</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="320">
          <ReferenceId>23569311</ReferenceId>
          <FullCitation>Gianni L, et al. J. Clin. Oncol. (2013) pmid: 23569311</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="321">
          <ReferenceId>23397155</ReferenceId>
          <FullCitation>Sánchez-Rovira P, et al. Clin Transl Oncol (2013) pmid: 23397155</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="322">
          <ReferenceId>23932548</ReferenceId>
          <FullCitation>Cameron D, et al. Lancet Oncol. (2013) pmid: 23932548</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="323">
          <ReferenceId>24807156</ReferenceId>
          <FullCitation>Mok T, et al. J Thorac Oncol (2014) pmid: 24807156</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="324">
          <ReferenceId>24577128</ReferenceId>
          <FullCitation>An SJ, et al. Cancer Gene Ther. (2014) pmid: 24577128</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="325">
          <ReferenceId>29059426</ReferenceId>
          <FullCitation>Bais C, et al. J. Natl. Cancer Inst. (2017) pmid: 29059426</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="326">
          <ReferenceId>19201650</ReferenceId>
          <FullCitation>Cohen EE, et al. Lancet Oncol. (2009) pmid: 19201650</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="327">
          <ReferenceId>22565005</ReferenceId>
          <FullCitation>Van Cutsem E, et al. J. Clin. Oncol. (2012) pmid: 22565005</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="328">
          <ReferenceId>29941486</ReferenceId>
          <FullCitation>Lee EQ, et al. Clin. Cancer Res. (2018) pmid: 29941486</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="329">
          <ReferenceId>19826039</ReferenceId>
          <FullCitation>Xu L, et al. Cancer Res. (2009) pmid: 19826039</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="330">
          <ReferenceId>25605928</ReferenceId>
          <FullCitation>Heist RS, et al. Proc. Natl. Acad. Sci. U.S.A. (2015) pmid: 25605928</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="331">
          <ReferenceId>19637194</ReferenceId>
          <FullCitation>Rabenhorst U, et al. Hepatology (2009) pmid: 19637194</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="332">
          <ReferenceId>19258502</ReferenceId>
          <FullCitation>Singer S, et al. Cancer Res. (2009) pmid: 19258502</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="333">
          <ReferenceId>22588899</ReferenceId>
          <FullCitation>Sahm F, et al. Acta Neuropathol. (2012) pmid: 22588899</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="334">
          <ReferenceId>21817013</ReferenceId>
          <FullCitation>Bettegowda C, et al. Science (2011) pmid: 21817013</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="335">
          <ReferenceId>24117486</ReferenceId>
          <FullCitation>Baumgarten P, et al. Neuropathol. Appl. Neurobiol. (2014) pmid: 24117486</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="336">
          <ReferenceId>24030748</ReferenceId>
          <FullCitation>Chan AK, et al. Mod. Pathol. (2014) pmid: 24030748</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="337">
          <ReferenceId>22869205</ReferenceId>
          <FullCitation>Jiao Y, et al. Oncotarget (2012) pmid: 22869205</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="338">
          <ReferenceId>30371878</ReferenceId>
          <FullCitation>Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="339">
          <ReferenceId>25030436</ReferenceId>
          <FullCitation>Jia MY, et al. Neoplasma (2014) pmid: 25030436</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="340">
          <ReferenceId>8125259</ReferenceId>
          <FullCitation>Duncan R, et al. Genes Dev. (1994) pmid: 8125259</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="341">
          <ReferenceId>12819782</ReferenceId>
          <FullCitation>Kim MJ, et al. Nat. Genet. (2003) pmid: 12819782</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="342">
          <ReferenceId>19087307</ReferenceId>
          <FullCitation>Weber A, et al. BMC Cancer (2008) pmid: 19087307</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="343">
          <ReferenceId>19219071</ReferenceId>
          <FullCitation>Jang M, et al. Oncogene (2009) pmid: 19219071</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="344">
          <ReferenceId>21855647</ReferenceId>
          <FullCitation>Zheng Y, et al. Int. J. Biochem. Cell Biol. (2011) pmid: 21855647</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="345">
          <ReferenceId>24798327</ReferenceId>
          <FullCitation>Jacob AG, et al. J. Biol. Chem. (2014) pmid: 24798327</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="346">
          <ReferenceId>18410249</ReferenceId>
          <FullCitation>Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="347">
          <ReferenceId>12826609</ReferenceId>
          <FullCitation>Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="348">
          <ReferenceId>20978130</ReferenceId>
          <FullCitation>Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="349">
          <ReferenceId>28472496</ReferenceId>
          <FullCitation>Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="350">
          <ReferenceId>17690113</ReferenceId>
          <FullCitation>Yamada H, et al. Carcinogenesis (2007) pmid: 17690113</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="351">
          <ReferenceId>32059776</ReferenceId>
          <FullCitation>Dou Y, et al. Cell (2020) pmid: 32059776</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="352">
          <ReferenceId>34998597</ReferenceId>
          <FullCitation>Lin DI, et al. Gynecol Oncol (2022) pmid: 34998597</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="353">
          <ReferenceId>22678923</ReferenceId>
          <FullCitation>Wild PJ, et al. EMBO Mol Med (2012) pmid: 22678923</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="354">
          <ReferenceId>20006376</ReferenceId>
          <FullCitation>Lee EJ, et al. Gynecol. Oncol. (2010) pmid: 20006376</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="355">
          <ReferenceId>35749374</ReferenceId>
          <FullCitation>Kim SP, et al. Cancer Immunol Res (2022) pmid: 35749374</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="356">
          <ReferenceId>20107315</ReferenceId>
          <FullCitation>Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="357">
          <ReferenceId>21799033</ReferenceId>
          <FullCitation>Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="358">
          <ReferenceId>21389100</ReferenceId>
          <FullCitation>Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="359">
          <ReferenceId>25504633</ReferenceId>
          <FullCitation>Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="360">
          <ReferenceId>12489850</ReferenceId>
          <FullCitation>Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="361">
          <ReferenceId>11713371</ReferenceId>
          <FullCitation>Xu L, et al. Mol. Med. (2001) pmid: 11713371</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="362">
          <ReferenceId>23470564</ReferenceId>
          <FullCitation>Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="363">
          <ReferenceId>25240597</ReferenceId>
          <FullCitation>Kim SS, et al. Nanomedicine (2015) pmid: 25240597</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="364">
          <ReferenceId>27357628</ReferenceId>
          <FullCitation>Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="365">
          <ReferenceId>27601554</ReferenceId>
          <FullCitation>Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="366">
          <ReferenceId>37236033</ReferenceId>
          <FullCitation>Embaby A, et al. Gynecol Oncol (2023) pmid: 37236033</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="367">
          <ReferenceId>31315834</ReferenceId>
          <FullCitation>Lee J, et al. Cancer Discov (2019) pmid: 31315834</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="368">
          <ReferenceId>29535125</ReferenceId>
          <FullCitation>Méndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="369">
          <ReferenceId>34538072</ReferenceId>
          <FullCitation>Seligmann JF, et al. J Clin Oncol (2021) pmid: 34538072</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="370">
          <ReferenceId>36084396</ReferenceId>
          <FullCitation>Park H, et al. ESMO Open (2022) pmid: 36084396</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="371">
          <ReferenceId>29165669</ReferenceId>
          <FullCitation>Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="372">
          <ReferenceId>26014290</ReferenceId>
          <FullCitation>Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="373">
          <ReferenceId>23355100</ReferenceId>
          <FullCitation>Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="374">
          <ReferenceId>11219776</ReferenceId>
          <FullCitation>Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="375">
          <ReferenceId>9006316</ReferenceId>
          <FullCitation>Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="376">
          <ReferenceId>19204208</ReferenceId>
          <FullCitation>Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="377">
          <ReferenceId>12672316</ReferenceId>
          <FullCitation>Lalloo F, et al. Lancet (2003) pmid: 12672316</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="378">
          <ReferenceId>31050713</ReferenceId>
          <FullCitation>Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="379">
          <ReferenceId>25426837</ReferenceId>
          <FullCitation>Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="380">
          <ReferenceId>25426838</ReferenceId>
          <FullCitation>Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="381">
          <ReferenceId>25326804</ReferenceId>
          <FullCitation>Xie M, et al. Nat. Med. (2014) pmid: 25326804</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="382">
          <ReferenceId>28669404</ReferenceId>
          <FullCitation>Acuna-Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="383">
          <ReferenceId>29678827</ReferenceId>
          <FullCitation>Severson EA, et al. Blood (2018) pmid: 29678827</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="384">
          <ReferenceId>29420212</ReferenceId>
          <FullCitation>Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="385">
          <ReferenceId>30504320</ReferenceId>
          <FullCitation>Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="386">
          <ReferenceId>32269342</ReferenceId>
          <FullCitation>Chabon JJ, et al. Nature (2020) pmid: 32269342</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="387">
          <ReferenceId>31768066</ReferenceId>
          <FullCitation>Razavi P, et al. Nat. Med. (2019) pmid: 31768066</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="388">
          <ReferenceId>24882554</ReferenceId>
          <FullCitation>Castonguay V, et al. Gynecol. Oncol. (2014) pmid: 24882554</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="389">
          <ReferenceId>18955458</ReferenceId>
          <FullCitation>Heinrich MC, et al. J. Clin. Oncol. (2008) pmid: 18955458</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="390">
          <ReferenceId>26264378</ReferenceId>
          <FullCitation>Buchbinder EI, et al. Cancer (2015) pmid: 26264378</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="391">
          <ReferenceId>26772734</ReferenceId>
          <FullCitation>Reichardt P, et al. BMC Cancer (2016) pmid: 26772734</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="392">
          <ReferenceId>27073655</ReferenceId>
          <FullCitation>Hirai F, et al. Mol Clin Oncol (2016) pmid: 27073655</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="393">
          <ReferenceId>20435347</ReferenceId>
          <FullCitation>Goemans BF, et al. Leuk. Res. (2010) pmid: 20435347</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="394">
          <ReferenceId>20117828</ReferenceId>
          <FullCitation>Nimeiri HS, et al. Gynecol. Oncol. (2010) pmid: 20117828</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="395">
          <ReferenceId>21098323</ReferenceId>
          <FullCitation>Matei D, et al. J. Clin. Oncol. (2011) pmid: 21098323</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="396">
          <ReferenceId>21723597</ReferenceId>
          <FullCitation>Bodnar L, et al. Gynecol. Oncol. (2011) pmid: 21723597</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="397">
          <ReferenceId>18936790</ReferenceId>
          <FullCitation>Quintás-Cardama A, et al. Nat Clin Pract Oncol (2008) pmid: 18936790</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="398">
          <ReferenceId>19461405</ReferenceId>
          <FullCitation>Bisagni G, et al. J Thorac Oncol (2009) pmid: 19461405</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="399">
          <ReferenceId>20372153</ReferenceId>
          <FullCitation>Handolias D, et al. Br. J. Cancer (2010) pmid: 20372153</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="400">
          <ReferenceId>20970876</ReferenceId>
          <FullCitation>Dişel U, et al. Lung Cancer (2011) pmid: 20970876</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="401">
          <ReferenceId>22270258</ReferenceId>
          <FullCitation>Park SH, et al. Invest New Drugs (2012) pmid: 22270258</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="402">
          <ReferenceId>24855380</ReferenceId>
          <FullCitation>Catania C, et al. Onco Targets Ther (2014) pmid: 24855380</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="403">
          <ReferenceId>17699867</ReferenceId>
          <FullCitation>Guo T, et al. Clin. Cancer Res. (2007) pmid: 17699867</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="404">
          <ReferenceId>18483300</ReferenceId>
          <FullCitation>Hu S, et al. Mol. Cancer Ther. (2008) pmid: 18483300</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="405">
          <ReferenceId>21892101</ReferenceId>
          <FullCitation>Tsao AS, et al. J Thorac Oncol (2011) pmid: 21892101</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="406">
          <ReferenceId>23033932</ReferenceId>
          <FullCitation>Bauman JE, et al. BMC Cancer (2012) pmid: 23033932</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="407">
          <ReferenceId>19933079</ReferenceId>
          <FullCitation>Yardley DA, et al. Clin. Breast Cancer (2009) pmid: 19933079</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="408">
          <ReferenceId>19073506</ReferenceId>
          <FullCitation>Chew HK, et al. Clin. Breast Cancer (2008) pmid: 19073506</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="409">
          <ReferenceId>18515258</ReferenceId>
          <FullCitation>Cristofanilli M, et al. Ann. Oncol. (2008) pmid: 18515258</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="410">
          <ReferenceId>20189232</ReferenceId>
          <FullCitation>Huh WK, et al. Gynecol. Oncol. (2010) pmid: 20189232</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="411">
          <ReferenceId>16624552</ReferenceId>
          <FullCitation>Debiec-Rychter M, et al. Eur. J. Cancer (2006) pmid: 16624552</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="412">
          <ReferenceId>14645423</ReferenceId>
          <FullCitation>Heinrich MC, et al. J. Clin. Oncol. (2003) pmid: 14645423</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="413">
          <ReferenceId>16570351</ReferenceId>
          <FullCitation>Kamenz T, et al. World J. Gastroenterol. (2006) pmid: 16570351</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="414">
          <ReferenceId>15650049</ReferenceId>
          <FullCitation>Wang YY, et al. Proc. Natl. Acad. Sci. U.S.A. (2005) pmid: 15650049</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="415">
          <ReferenceId>24335106</ReferenceId>
          <FullCitation>Hughes TP, et al. Blood (2014) pmid: 24335106</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="416">
          <ReferenceId>24650752</ReferenceId>
          <FullCitation>Takahashi N, et al. Biomark Res (2014) pmid: 24650752</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="417">
          <ReferenceId>22357255</ReferenceId>
          <FullCitation>Reichardt P, et al. Ann. Oncol. (2012) pmid: 22357255</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="418">
          <ReferenceId>22119758</ReferenceId>
          <FullCitation>Cauchi C, et al. Cancer Chemother. Pharmacol. (2012) pmid: 22119758</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="419">
          <ReferenceId>25695690</ReferenceId>
          <FullCitation>Carvajal RD, et al. Clin. Cancer Res. (2015) pmid: 25695690</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="420">
          <ReferenceId>26002753</ReferenceId>
          <FullCitation>Hochhaus A, et al. J. Cancer Res. Clin. Oncol. (2015) pmid: 26002753</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="421">
          <ReferenceId>25882987</ReferenceId>
          <FullCitation>Blay JY, et al. Lancet Oncol. (2015) pmid: 25882987</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="422">
          <ReferenceId>26722383</ReferenceId>
          <FullCitation>Kajimoto N, et al. Int J Clin Exp Pathol (2015) pmid: 26722383</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="423">
          <ReferenceId>25221952</ReferenceId>
          <FullCitation>Sako H, et al. PLoS ONE (2014) pmid: 25221952</FullCitation>
          <Include>true</Include>
        </Reference>
      </References>
      <Signatures>
        <Signature>
          <ServerTime>2024-01-16 22:47:25</ServerTime>
          <OpName>Erik Williams, M.D. | Lauren L. Ritterhouse Casariego, M.D., Ph.D., Laboratory Director</OpName>
          <Text>Erik Williams, M.D. | Lauren L. Ritterhouse Casariego, M.D., Ph.D., Laboratory Director</Text>
        </Signature>
      </Signatures>
      <reportProperties>
        <reportProperty identifier="QualityControlMetrics" key="MedianCoverageValue">
          <value>905x</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="TumorMutationBurdenScore">
          <value>7 Muts/Mb</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="MicrosatelliteStatusScore">
          <value>0 fraction-unstable-loci</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="LossOfHeterozygosityScore">
          <value>Units Not Reported</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="BloodTumorMutationalBurdenScore">
          <value>Units Not Reported</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="TumorFractionScore">
          <value>Units Not Reported</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="ComprehensiveTumorFractionScore">
          <value>Units Not Reported</value>
        </reportProperty>
      </reportProperties>
      <comments />
      <AAC>
        <Amendmends />
      </AAC>
    </FinalReport>
    <variant-report xmlns="http://foundationmedicine.com/compbio/variant-report-external" disease="UTERUS" disease-ontology="Uterus endometrial adenocarcinoma papillary serous" flowcell-analysis="2000033234" gender="female" pathology-diagnosis="Carcinoma" percent-tumor-nuclei="40" pipeline-version="v3.29.0" purity-assessment="19.82" specimen="ORD-1794439-01*US1709714.01" study="CLINICAL-F1CDx v2" test-request="ORD-1794439-01" test-type="FoundationOneDx" tissue-of-origin="Uterus" xsi:schemaLocation="http://foundationmedicine.com/compbio/variant-report-external http://integration.foundationmedicine.com/reporting/variant-report-external-2.2.xsd">
      <samples>
        <sample bait-set="DX2" mean-exon-depth="928.58" name="SQ-US1709714.01-1" nucleic-acid-type="DNA" />
      </samples>
      <quality-control status="Pass" />
      <short-variants>
        <short-variant allele-fraction="0.1343" cds-effect="691C&gt;A" depth="737" equivocal="false" functional-effect="missense" gene="ATM" percent-reads="13.43" position="chr11:108115543" protein-effect="H231N" status="unknown" strand="+" transcript="NM_000051">
          <dna-evidence sample="SQ-US1709714.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.1967" cds-effect="136G&gt;A" depth="910" equivocal="false" functional-effect="missense" gene="SPOP" percent-reads="19.67" position="chr17:47699372" protein-effect="E46K" status="known" strand="-" transcript="NM_003563">
          <dna-evidence sample="SQ-US1709714.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.4428" cds-effect="10024C&gt;T" depth="1023" equivocal="false" functional-effect="missense" gene="MLL2" percent-reads="44.28" position="chr12:49431115" protein-effect="R3342C" status="unknown" strand="-" transcript="NM_003482">
          <dna-evidence sample="SQ-US1709714.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.1648" cds-effect="1436G&gt;A" depth="904" equivocal="false" functional-effect="missense" gene="FBXW7" percent-reads="16.48" position="chr4:153247366" protein-effect="R479Q" status="known" strand="-" transcript="NM_033632">
          <dna-evidence sample="SQ-US1709714.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.5472" cds-effect="823C&gt;G" depth="963" equivocal="false" functional-effect="missense" gene="BCORL1" percent-reads="54.72" position="chrX:129147571" protein-effect="L275V" status="unknown" strand="+" transcript="NM_021946">
          <dna-evidence sample="SQ-US1709714.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.0615" cds-effect="2227C&gt;G" depth="975" equivocal="false" functional-effect="missense" gene="SPEN" percent-reads="6.15" position="chr1:16254962" protein-effect="Q743E" status="unknown" strand="+" transcript="NM_015001">
          <dna-evidence sample="SQ-US1709714.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.4741" cds-effect="1495C&gt;T" depth="888" equivocal="false" functional-effect="missense" gene="ASXL1" percent-reads="47.41" position="chr20:31021496" protein-effect="R499C" status="unknown" strand="+" transcript="NM_015338">
          <dna-evidence sample="SQ-US1709714.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.0305" cds-effect="1780G&gt;A" depth="753" equivocal="false" functional-effect="missense" gene="BRAF" percent-reads="3.05" position="chr7:140453155" protein-effect="D594N" status="known" strand="-" transcript="NM_004333">
          <dna-evidence sample="SQ-US1709714.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.0595" cds-effect="3455C&gt;T" depth="1160" equivocal="false" functional-effect="missense" gene="SPEN" percent-reads="5.95" position="chr1:16256190" protein-effect="S1152L" status="unknown" strand="+" transcript="NM_015001">
          <dna-evidence sample="SQ-US1709714.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.6092" cds-effect="1481C&gt;T" depth="586" equivocal="false" functional-effect="missense" gene="DIS3" percent-reads="60.92" position="chr13:73345967" protein-effect="A494V" status="unknown" strand="-" transcript="NM_001128226">
          <dna-evidence sample="SQ-US1709714.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.4791" cds-effect="1629A&gt;G" depth="1171" equivocal="false" functional-effect="missense" gene="DAXX" percent-reads="47.91" position="chr6:33287468" protein-effect="I543M" status="unknown" strand="-" transcript="NM_001350">
          <dna-evidence sample="SQ-US1709714.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.1058" cds-effect="3987G&gt;C" depth="794" equivocal="false" functional-effect="missense" gene="CIC" percent-reads="10.58" position="chr19:42797935" protein-effect="K1329N" status="unknown" strand="+" transcript="NM_015125">
          <dna-evidence sample="SQ-US1709714.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.1088" cds-effect="4081G&gt;C" depth="800" equivocal="false" functional-effect="missense" gene="CIC" percent-reads="10.88" position="chr19:42798127" protein-effect="E1361Q" status="unknown" strand="+" transcript="NM_015125">
          <dna-evidence sample="SQ-US1709714.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.4616" cds-effect="1398C&gt;G" depth="912" equivocal="false" functional-effect="missense" gene="TNFAIP3" percent-reads="46.16" position="chr6:138199980" protein-effect="S466R" status="unknown" strand="+" transcript="NM_006290">
          <dna-evidence sample="SQ-US1709714.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.1306" cds-effect="742C&gt;T" depth="720" equivocal="false" functional-effect="missense" gene="TP53" percent-reads="13.06" position="chr17:7577539" protein-effect="R248W" status="known" strand="-" transcript="NM_000546">
          <dna-evidence sample="SQ-US1709714.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.3115" cds-effect="131G&gt;A" depth="777" equivocal="false" functional-effect="missense" gene="MED12" percent-reads="31.15" position="chrX:70339254" protein-effect="G44D" status="known" strand="+" transcript="NM_005120">
          <dna-evidence sample="SQ-US1709714.01-1" />
        </short-variant>
      </short-variants>
      <copy-number-alterations>
        <copy-number-alteration copy-number="10" equivocal="false" gene="PDGFRA" number-of-exons="22 of 22" position="chr4:55124895-55161439" ratio="1.83" status="known" type="amplification">
          <dna-evidence sample="SQ-US1709714.01-1" />
        </copy-number-alteration>
        <copy-number-alteration copy-number="7" equivocal="true" gene="TBX3" number-of-exons="8 of 8" position="chr12:115109645-115121005" ratio="1.55" status="unknown" type="amplification">
          <dna-evidence sample="SQ-US1709714.01-1" />
        </copy-number-alteration>
        <copy-number-alteration copy-number="10" equivocal="false" gene="MDM2" number-of-exons="9 of 11" position="chr12:69207306-69233685" ratio="1.79" status="known" type="amplification">
          <dna-evidence sample="SQ-US1709714.01-1" />
        </copy-number-alteration>
        <copy-number-alteration copy-number="6" equivocal="true" gene="KIT" number-of-exons="21 of 21" position="chr4:55524150-55604723" ratio="1.44" status="known" type="amplification">
          <dna-evidence sample="SQ-US1709714.01-1" />
        </copy-number-alteration>
        <copy-number-alteration copy-number="13" equivocal="false" gene="MYC" number-of-exons="5 of 5" position="chr8:128748789-128753204" ratio="2.13" status="known" type="amplification">
          <dna-evidence sample="SQ-US1709714.01-1" />
        </copy-number-alteration>
        <copy-number-alteration copy-number="21" equivocal="false" gene="CCNE1" number-of-exons="10 of 10" position="chr19:30303588-30314684" ratio="2.98" status="known" type="amplification">
          <dna-evidence sample="SQ-US1709714.01-1" />
        </copy-number-alteration>
        <copy-number-alteration copy-number="6" equivocal="true" gene="KDR" number-of-exons="30 of 30" position="chr4:55946107-55991491" ratio="1.46" status="known" type="amplification">
          <dna-evidence sample="SQ-US1709714.01-1" />
        </copy-number-alteration>
      </copy-number-alterations>
      <rearrangements>
        <rearrangement allele-fraction="0.0261" description="KDR(NM_002253) rearrangement exon 13" equivocal="false" in-frame="unknown" other-gene="N/A" percent-reads="2.61" pos1="chr4:55970849" pos2="chrX:142972600" status="unknown" supporting-read-pairs="71" targeted-gene="KDR" type="rearrangement">
          <dna-evidence sample="SQ-US1709714.01-1" />
        </rearrangement>
        <rearrangement allele-fraction="0.0242" description="FUBP1(NM_003902) deletion intron 1 - exon 11" equivocal="false" in-frame="unknown" other-gene="FUBP1" percent-reads="2.42" pos1="chr1:78430021" pos2="chr1:78437714" status="likely" supporting-read-pairs="51" targeted-gene="FUBP1" type="deletion">
          <dna-evidence sample="SQ-US1709714.01-1" />
        </rearrangement>
      </rearrangements>
      <biomarkers>
        <microsatellite-instability status="MSS" />
        <tumor-mutation-burden score="7.24" status="intermediate" unit="mutations-per-megabase" />
      </biomarkers>
      <non-human-content />
    </variant-report>
  </rr:ResultsPayload>
</rr:ResultsReport>
